Synthesis and Evaluation of Densely-Functionalized Troponoids by Hirsch, Danielle R
City University of New York (CUNY)
CUNY Academic Works
Dissertations, Theses, and Capstone Projects Graduate Center
9-2018
Synthesis and Evaluation of Densely-
Functionalized Troponoids
Danielle R. Hirsch
The Graduate Center, City University of New York
How does access to this work benefit you? Let us know!
Follow this and additional works at: https://academicworks.cuny.edu/gc_etds
Part of the Organic Chemistry Commons
This Dissertation is brought to you by CUNY Academic Works. It has been accepted for inclusion in All Dissertations, Theses, and Capstone Projects
by an authorized administrator of CUNY Academic Works. For more information, please contact deposit@gc.cuny.edu.
Recommended Citation










SYNTHESIS AND EVALUATION OF DENSELY-FUNCTIONALIZED TROPONOIDS 
by 









A dissertation submitted to the Graduate Faculty in Chemistry in partial fulfillment of the 


























DANIELLE R. HIRSCH 
All Rights Reserved 
iii 
 
Synthesis and Evaluation of Densely-Functionalized Troponoids  
 
by 
Danielle R. Hirsch 
 
This manuscript has been read and accepted for the Graduate Faculty in 
Chemistry in satisfaction of the dissertation requirement for the degree of  






Date  Ryan P. Murelli 
Chair of Examining Committee 


























Synthesis and Evaluation of Densely-Functionalized Troponoids 
by 
Danielle R. Hirsch 
Advisor: Ryan P. Murelli 
 
 Herein, we document our efforts to expand the scope of troponoid synthetic methodology 
towards densely-substituted scaffolds. This body of work has focused primarily on an 
oxidopyrylium cycloaddition/ring-opening strategy for the synthesis and biochemical evaluation 
of troponoids for assistance in a variety of medicinal chemistry studies. In Chapter 1, we outline 
the use of this synthetic strategy in the profiling of a library of synthetic αHTs against an 
aminoglycoside antibiotic resistance enzyme known as aminoglycoside-2’’-O-
nucleotidyltransferase [ANT(2’’)-Ia]. Enzymatic mechanistic insights have been gleaned from an 
assessment of troponoid/antibiotic synergistic potential. In particular, two synthetic constructs 
were identified as promising antibiotic adjuvant candidates, demonstrating a capacity to rescue 
gentamicin activity while in the presence of ANT(2’’)-Ia-expressing bacteria. These results 
validate the oxidopyrylium cycloaddition/ring-opening method as a viable approach to generating 
new ANT(2’’)-Ia inhibitors, and provide some preliminary insight into the structural changes 
required for effective inhibition. 
 In Chapter 2, we report the expansion of this synthetic strategy to a class of molecules 
called 3,7-dihydroxytropolones, which have been indicated as promising leads in the development 
of antiviral, antimelanoma and antimalarial agents. These synthetic developments were applied in 
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the synthesis of a prospective biosynthetic precursor to the natural products puberulic and 
puberulonic acid. Additionally, several new synthetic 3,7-dihydroxytropolones were identified as 
promising scaffolds for anti-HSV drug development. This synthetic work was further expanded 
towards additional investigations on the synthesis and physical evaluation of atropisomeric 
troponoids, as discussed in Chapters 3 and 4. The research described within these chapters aims to 
broaden our understanding of the physical properties of troponoids by using DFT and experimental 
techniques to assess the rotational barriers of a series of benzenoid and troponoid scaffolds, as well 
as by studying the atropselective bromination of a methoxytropolone. During the course of these 
studies, 1H- and 13C-NMR experiments unveiled several mechanistic findings pertinent to future 
development of the reaction.   
 Collectively, the studies described in this thesis aim to broaden our understanding of the 
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Synthesis and Biological Activity of α-Hydroxytropolones 
1.1 Introduction to α-Hydroxytropolones  
α-Hydroxytropolones (αHTs) are a subset of the troponoid family of natural products1  that 
possess therapeutic potential against a wide variety of disease targets.2 Structurally, the 
molecules represent non-benzenoid aromatic ring scaffolds with a contiguous array of three 
oxygen atoms (1.1a, αHTs) or four oxygens (1.1b, 3,7-dihydroxytropones [3,7-dHTs], vide 
infra). Under certain basic conditions, αHTs can adopt a dianionic form, which is capable of 
delocalizing charge throughout the molecule resulting in a trident-like assemblage of negatively 
charged oxygen atoms (Figure 1.1).3 This makes them exceptional inhibitors of dinuclear 
metalloenzymes.2,4 Studies on natural products β-thujaplicinol 1.2 and manicol 1.3 have 
demonstrated that αHTs can exhibit potent activity against hepatitis B virus (HBV),5 human 
immunodeficiency virus (HIV),6 herpes simplex virus 1 and 2 (HSV-1 and -2),7 and an 
aminoglycoside resistance enzyme, ANT(2’’)-Ia.8 
 
 
1.2. Synthetic Routes Towards α-Hydroxytropolones 
Synthetic routes towards αHTs have historically focused on a variety of strategies 
summarized in Scheme 1.1.  One of the earliest reports of troponoid total synthesis was 
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published in 1960. Nozoe and coworkers were able to synthesize 3,7-dHT natural product 
puberulonic acid 1.6 via a series of brominations and hydolyzations on purpurogallin 1.4 
(Scheme 1.1A).9 While this is an effective method of generating hydroxylated tropones, it 
suffers from a low yielding first step. Additionally, this oxidation-driven approach starts with the 
full structural framework on purpurogallin and no new carbon-carbon bonds are formed – as 
such, it does not lend itself well to generating diverse substitution patterns. 
 
 Around the same time, a cyclopropanation/ring-opening approach was developed by 
Johnson and coworkers that addressed several of these limitations (Scheme 1.1B).  
1,2,3-Trimethoxybenzene 1.7 was treated with ethyldiazoacetate and subsequently underwent a 
6π-electrocyclic ring-opening followed by hydrolysis and oxidation to generate 3,7-dHT natural 
product puberulic acid.10a-c Along the same lines, Balci and coworkers more recently were able 
to generate αHT 1.12 via a cyclopropanation/6π-electrocyclic ring-opening on benzenoid 1.10 
followed by a singlet oxygen-mediated rearrangement of 1.11 (Scheme 1.1C).10d  
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 In contrast to these cyclopropanation approaches which are followed by 6π-electrocyclic 
ring-openings, Banwell and coworkers developed a strategy leveraging cyclopropanated 
intermediates in Grob fragmentations for the generation of troponoid natural products 
β-thujaplicinol 1.211 (Scheme 1.1D) and puberulic acid 1.912 (vide infra). A notable advantage 
provided by this approach is the accessibility of bromotroponoid intermediates stemming from 
1.14, which can be functionalized through cross-coupling11 and demethylated to generate 
αHTs.13 An additional cyclopropanation approach was utilized several years later by Davies and 
coworkers towards dimethoxytropolones 1.17.10e While not applied directly to αHTs, this method 
granted quick access (only four steps from vinyl diazo carbonyl 1.15) to intermediates that are a 
simple demethylation away from αHTs (Scheme 1.1E). 
 More recently, a cycloaddition/ring-opening approach was reported by Föhlisch and 
coworkers (Scheme 1.1F).14 Starting with substituted furans 1.18 and pentachloroacetone, 
8-oxabicyclo[3.2.1]octenes 1.19 were generated via a cycloaddition. These modifiable 
intermediates were subsequently treated to a base-mediated ring-opening followed by 
demethylation to provide αHTs 1.20, including β-thujaplicinol 1.2.  
 
1.3. Previous Synthetic Chemistry-Driven Biological Studies on α-Hydroxytropolones 
 Despite the scope of studied synthetic approaches to αHTs as well as their promising 
therapeutic potential, there has existed a surprising lack of SAR-amenable general synthetic 
routes to access them.2 Fortunately, bioactive natural products can provide a suitable starting 
point for synthetic derivatization, as was demonstrated by Le Grice and coworkers.6e In this 
work, the alkene moiety of natural product manicol (1.3, Figure 1.2) was functionalized via 




While none of the 13 new αHT constructs exhibited significant advantages over the natural 
product lead in enzymatic assays, all were active. More importantly, unlike manicol, some of the 
analogs were capable of inhibiting viral replication in cell-based assays. Furthermore, many of 
the analogs were also significantly less cytotoxic than manicol. This study demonstrates the 
importance of synthesis in medicinal chemistry studies. 
In a similar vein, Piettre and coworkers were able to synthesize a series of arylated 
3,7-dihydroxytropolones by modifying an existing troponoid.15 This synthetic work was utilized 
in SAR studies on inhibition of inositol monophosphatase (IMPase), an enzyme implicated in 
bipolar disorder and manic depression. They were able to generate compounds 1.24 and 1.25 in a 
4.7:1 ratio (Scheme 1.2). These compounds were then protected with methyl groups using 
diazomethane, subjected to Suzuki cross-couplings using a variety of arylboronic acids, and 
subsequently deprotected with TMSI/MeCN. While they were able to synthesize 37 new 
dihydroxytropolones and subsequently screen them for their inhibitory activity against IMPase, 
their best molecule tested had only a slight increase in potency over the parent compound.  
Marquet and coworkers followed a similar oxidation/cross-coupling method to synthesize 
arylated dihydroxytropolone analogs in an effort to develop broad activity HIV retroviral 
hydroxytropolones.6b They were able to generate compounds 1.24 and 1.25 and carry them 
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through the subsequent Suzuki cross-coupling to generate a series of dihydroxytropolones 
1.26a-c, which lead to some improved analogs against specific antiretroviral enzymes (Scheme 
1.2). However, none of them were reported to have improved HIV replication activity over the 
parent compound, and all proved to be inactive in an HIV-1 cellular assay. Synthetically, the 
method is limited in that the initial bromination only goes to 57% conversion and gives a mixture 
of products.  
 
De novo synthetic methods offer opportunity to gain access to a more structurally diverse 
group of molecules. One additional approach was developed by Banwell and coworkers, who 
were able to accomplish late-stage introduction of substitution on αHTs.16 This method was used 
to synthesize natural products β-thujaplicinol (vide supra)11 and puberulic acid (Scheme 1.3).12  
 
While this method provides a route to modifiable late-stage synthetic intermediates and is viable 
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from a structure-function standpoint, it is problematic in practice. The synthesis is long (10 steps) 
and only allows access to one position on the αHT ring.        
 
1.4. Murelli Synthesis and Antiviral Assessment of αHTs 
As a method of overcoming these limitations, earlier work done in our lab based on 
established [5C + 2C] cycloadditions17 showed that 8-oxabicyclo[3.2.1]octenes 1.32 can be 
accessed through an intermolecular dipolar cycloaddition of kojic acid-derived salts 1.30 and 
diversely-substituted alkynes 1.31 (Scheme 1.4).18  
 
A key advantage of this approach is the introduction of functionality via readily available, 
structurally diverse alkynes. Notably, salt 1.30 and related ylide sources have also found utility 
in catalytic, asymmetric [5 + 2] dipolar cycloadditions,19 most recently with an array of 
α,β-unsaturated aldehyde dipolarophiles,20 demonstrating the widespread utility of this starting 
material.  Moreover, 1.30a can be synthesized on a large scale from kojic acid, which is a very 
inexpensive byproduct of sake production.21 Owing to the ease with which large quantities of 
this salt can be synthesized, triflate salt 1.30a becomes a de facto starting material. Thus, 
diversely substituted 8-oxabicyclo[3.2.1] octenes 1.32 are  readily synthesized in one step. 
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These bicyclic intermediates can undergo an acid-mediated ring-opening18,22 and 
demethylation to generate multi-substituted αHTs in few steps from readily available 3-hydroxy-
4-pyrones (kojic acid). This route has proven to be useful in a broad range of optimization-driven 
medicinal chemistry studies. Chiefly, it has been used to assess the antiviral properties of these 
molecules. 
Much of these medicinal chemistry efforts have been geared towards the development of 
anti-HSV compounds. HSV-1 and -2 are highly related and destructive pathogens which 
currently infect almost 4 billion people worldwide.23,24 They chronically infect superficially 
damaged skin and mucosal surfaces, where they gain access to the nervous system and establish 
lifelong latency. In addition to ulcerative diseases, they are also associated with a rare form of 
encephalitis as well as corneal blindness.25 The current first line of treatment includes nucleoside 
analog drugs such as acyclovir (ACV) and cidofovir (CDV).26-28 However, these clinical agents 
are not completely effective, and the emergence of drug-resistant strains impedes efforts to 
control HSV, particularly in immunocompromised adults29 and children.30 This drug resistance 
therefore necessitates the development of new therapeutics.  
Towards this end, Tavis, Morrison, and coworkers demonstrated that αHT natural 
products manicol and β-thujaplicinol could inhibit wild-type and ACV-resistant HSV-1 and -2 
replication in cellular assays.31 Our lab subsequently synthesized and tested a library of αHTs 
against HSV to assess their viability as drug candidates.32 Among the top molecules to emerge 
from this study was biphenyl 1.35, which exhibited nanomolar inhibition in HSV replication 





Subsequent studies were conducted in an attempt to determine the binding target of 
biphenyl αHT 1.35. Due to structural similarities with HIV RT RNase H,33 dinuclear 
metalloenzyme terminase pUL15C emerged as a likely candidate, and thus an αHT-based SAR 
study was conducted on this target in collaboration with Le Grice and coworkers.34 The best 
molecule to emerge from the series was bromotropolone 1.36, which displayed improved binding 
over the natural product lead in both inhibition and thermal stabilization experiments (Figure 
1.4). However, antiviral lead 1.35 was found to bind weakly to pUL15C, suggesting that this 





Nevertheless, the promising anti-HSV activity of αHTs has spurred SAR studies on other 
members of the Herpesviridae family, most recently focused on Kaposi’s sarcoma herpesvirus 
(KSHV).36 KSHV is the causative agent of Kaposi’s sarcoma,37 which remains one of the most 
common cancers in people living with HIV.38 The virus is also responsible for certain types of 
lymphomas and multicentric Castleman’s disease. These fatal diseases are currently largely 
untreatable due to a lack of effective therapies.39 Therefore, new molecules are needed in order 
to combat KSHV.  
Fortunately, KSHV features a pUL15C-like terminase known as pORF29C, which we 
considered a possible target for αHT inhibition. We thus examined inhibition of this enzyme by a 
library of synthetic αHTs36 and discovered that dimethylester 1.37 demonstrated significant 
thermal stabilization (Figure 1.5). As an extension of this finding, we sought to identify an 
inhibitor of KSHV replication. Based on prior HSV studies,34 biphenyl 1.35 was analyzed. As 
KSHV is primarily latent in the infected host, it must be reactivated in order to be susceptible to 
an antiviral agent, and so these assays were run in a tetracycline repressed (TREx) latently 
infected cell line in the presence of a known activator doxycycline. As expected, viral replication 
was significantly reduced in the presence of DNA polymerase inhibitor phosphonoacetic acid 
(PAA, 1.38). However, synthetic αHT 1.35 emerged as a more potent inhibitor, further reducing 
viral growth at a significantly lower concentration than that of 1.38. At this same concentration 
of 5 μM, 1.35 induced no cell death and so the antiviral effect is not due to cytotoxicity. These 




Synthetic αHTs have also demonstrated promising inhibitory activity towards dinuclear 
metalloenzymes in other viral targets. Based on previous SAR studies focused on αHT inhibition 
of HIV RT RNase H (vide supra),6e we tested our library of αHTs against this enzyme.40 
Bromotropolone 1.36 was again identified as a potent substrate in both inhibition and thermal 
stabilization assays. The molecules were additionally screened against HBV RT RNase H,41 and 
while none of the synthetic constructs demonstrated improved enzymatic activity over the natural 
product lead β-thujaplicinol, methyl ketone 1.39 was found to inhibit HBV viral replication with 
an EC50 of 340 nM (Figure 1.6). This infers a therapeutic index of ~100 – a 4-fold increase over 








 Although the majority of our ongoing research has been aimed at antiviral developments, 
αHTs have demonstrated value towards other disease targets.  The remainder of this chapter will 
focus on αHT activity towards the aminoglycoside antibiotic resistance enzyme aminoglycoside-
2’’-O-nucleotidyltransferase [ANT(2’’)-Ia]. This enzyme is prevalent among Gram-negative 
bacteria and is one of the most common determinants of enzyme-dependent aminoglycoside 
resistance.42 Our oxidopyrylium cycloaddition/ring-opening strategy was used in the synthesis 
and profiling of a library of synthetic αHTs against ANT(2’’)-Ia.43  
 
1.5. Introduction to ANT(2’’)-Ia 
Antibiotic resistance is a global health threat that jeopardizes not only our ability to treat 
bacterial infections, but healthcare as we know it.44 Besides lifestyle changes,44f one strategy to 
overcome resistance is to inhibit or disrupt resistance pathways in the form of antibiotic 
adjuvants.45 For example, clavulanic acid is a β-lactamase inhibitor commonly used in tandem 




Aminoglycoside antibiotics are also prone to this type of enzymatic deactivation.47 One 
of these enzymes is ANT(2’’)-Ia, which catalyzes the adenylation of several clinically relevant 
antibiotics including gentamicin and tobramycin, rendering them inactive (Scheme 1.6).48 This 
target is prevalent among pathogenic Gram-negative bacteria, and has been ranked along with 
N-acetyltransferase-6’ [AAC-(6’)] as the most common determinant of enzyme-dependent 
aminoglycoside resistance in Pseudomonas aeruginosa.49 This is of particularly high clinical 
relevance, as P. aeruginosa is the most common hospital-acquired Gram-negative infection. 
Thus, inhibitors of ANT(2’’)-Ia could potentially find therapeutic utility when used in 




 αHT, along with αHT natural product β-thujaplicinol, were identified as inhibitors of 
ANT(2’’)-Ia in a 1982 study by researchers at Eli Lilly.50 Tropolone, meanwhile, showed no 
activity against the enzyme, illustrating the importance of the 3 contiguous oxygens. While 
several compounds have emerged for targeting aminoglycoside-modifying enzymes,51 in 
particular aminoglycoside mimics,52 ANT(2’’)-Ia inhibitors have been elusive,53 and αHTs 
remain one of the only leads. 
 
1.6. Preliminary Substrate Scope and SAR 
 Our oxidopyrylium cycloaddition/ring-opening synthetic strategy was used in a 
structure-function study of ANT(2’’)-Ia.43 The enzyme was overexpressed in Escherichia coli 
BL21 (λDE3), and activity was monitored in 96 well format through the detection of 
pyrophosphate (EnzCheck pyrophosphate assay), a by-product of the adenylation of gentamicin 
(Scheme 1.6). All biological work was carried out by Prof. Gerard Wright and Dr. Georgina 
Cox. Previously described synthetic α-hydroxytropolones18,22a and natural product 
β-thujaplicinol were tested for their inhibitory activity through an in vitro screen to obtain IC50 
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values (Table 1.1). Ki experiments were obtained on active compounds (IC50 < 200 μM) through 
dose curves with ATP and kanamycin B substrates.  
 Among the compounds tested, β-thujaplicinol was found to be capable of inhibiting the 
enzyme with the greatest potency, with a Ki value of 6.4 μM. While the majority of the 
synthesized molecules showed no inhibition of the enzyme, methyl ketone 1.39 and nitroaryl 
1.54 demonstrated some inhibitory potency. Notably, these compounds were among the least 
sterically demanding of the substrates tested and were approximately 5-10 fold less potent than 







1.7. Speculation on Binding Mode 
Previous studies suggest that the adenylation of ANT(2’’)-Ia may proceed via a 
mechanism involving the two magnesium ions in the catalytic pocket of the enzyme.54 
Additionally, prior studies on αHT inhibition of ANT(2’’)-Ia demonstrated that activity is 
influenced more substantially by ATP than by the aminoglycoside antibiotic.8 This trend was 
also observed in our own studies. Furthermore, while direct binding of αHTs to ATP cannot be 
entirely discounted, this mechanism of action appears unlikely due to the discrepancy between 
the concentration of ATP (35 μM) and the observed IC50 values (as low as 6 μM) in the 
inhibition assays.  
More likely, the αHTs inhibit via competitive action with respect to ATP. In the instances 
where Ki values were determined, all compounds demonstrated competitive inhibition with 
respect to ATP and mixed inhibition with respect to the antibiotic. This suggests that αHTs bind 
at or close to the ATP binding site, which is further supported by crystallographic data of 
αHT-bound HIV RT RNase H (Figure 1.7A). These cocrystal structures exhibit a metal-metal 
bond distance comparable to that found in an ATP-dinuclear enzyme complex (3.76 Å vs 3.91 Å, 
respectively)55 (Figure 1.7B). Furthermore, recent crystallographic data54b,c of ANT(2’’)-Ia in 
ternary complex with a nonhydrolyzable ATP analog (α,β-methyleneadenosine 5’-triphosphate 
lithium salt, AMPCPP) and gentamicin shows coordination of both divalent metal ions by 
AMPCPP phosphate groups as well as several Asp residues (Figure 1.7C).54c This suggests that 
the magnesium ions function as mediators of ATP transfer to the aminoglycoside substrate. αHT 





Furthermore, tropolone is generally inactive against ANT(2’’)-Ia, and additional 
methylated congeners of active compounds 1.39 and 1.54 (1.39a and 1.54a respectively, Table 
1.1) accessible through our synthetic method were also found to be inactive. While this could be 
due to other effects such as steric impacts of the added methyl group, this data is consistent with 
a dimetallic chelation binding mode.   
 
1.8. Follow-Up Substrate Scope and SAR 
We subsequently began to synthesize derivatives of the two lead synthetic αHTs, 1.39 
and 1.54. Using the same oxidopyrylium cycloaddition/ring-opening route, a series of analogs 
was generated and assayed (Table 1.2). Among the ketones tested, only isopropyl ketone 1.62 
showed any significant activity, which was comparable to 1.39. Cyclohexyl derivatives 1.63 and 
1.64 were inactive, potentially due to the aforementioned steric demands of the binding pocket. 
Additional support for the hypothesis of a sterically demanding enzymatic pocket can be 
found among the aryl series. Phenyl derivative 1.56 demonstrated comparable activity to parent 
molecule 1.54, while naphthyl derivatives 1.57 and 1.58 showed no activity. Comparisons 
among electron-withdrawing-substituted aryls further support this hypothesis. Halogenated 
analogs 1.59 and 1.60 both showed an almost 4-fold increase in activity over the other synthetic 
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constructs; meanwhile, trifluoromethyl aryl 1.61 demonstrated no inhibition of the enzyme, 





1.9. Assessment of Synergistic Activity 
With a series of ANT(2’’)-Ia-inhibiting troponoids in hand, we subsequently sought to 
assess whether these molecules could rescue the activity of aminoglycoside antibiotics against 
ANT(2’’)-Ia-expressing bacteria. Occasionally, molecules that demonstrate potent enzymatic 
activity will show a lack of antibacterial activity in cells.56  This is typically attributed to issues 
with cell permeability and/or the molecule being removed from the cell via efflux pumps. 
Therefore, a hyper-permeable, ANT(2’’)-Ia-expressing strain of E. coli BW25113 was 
constructed,57 leading to gentamicin resistance (MIC of 64 μg/mL vs. 0.25 μg/mL for wild type). 
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These bacteria were treated with gentamicin and the αHTs in a checkerboard fashion in order to 
assess their ability to potentiate the activity of the antibiotic (Figure 1.8).  
 Quantitatively, synergy can be determined by calculating each molecule’s FIC index 





FICI values of less than 0.5 are considered indicative of synergistic activity, while values of 0.5 
– 4 are classified as indicative of no interaction, and FICI values > 4 demonstrate antagonistic 
activity.45 Qualitatively, the shaded portions of the 2D graphs of synergistic molecules (FICI < 




 Consistent with the previous reports from Eli Lilly,8 β-thujaplicinol demonstrated 
synergy with gentamicin in our experiments (FICI = 0.375). As a negative control, an alternative 
enzyme conferring resistance to gentamicin (aminoglycoside phosphotransferase [APH(2’’)-Id]) 
that is uninhibited by αHTs was expressed by E. coli. β-thujaplicinol showed no synergy with 
this enzyme, which indicates that this activity is likely due to inhibition specifically of 
ANT(2’’)-Ia and not simply of ATP-binding proteins.  
 Synergistic activity was also observed with ketones 1.39 and 1.62. ANT(2’’)-Ia-
inhibiting biaryls 1.54, 1.55, 1.59 and 1.60 were all synergistically inactive. While the reason for 
this activity is currently unclear, a few possibilities exist such as low cell permeability, active 
efflux from the cell, and off-target interactions of the αHTs.  
 Interestingly, the checkerboard analysis revealed a difference in relative activity between 
β-thujaplicinol and synthetic construct 1.39. At 12 μM of β-thujaplicinol and 1.39, gentamicin 
had an MIC of 8 μg/mL and 32 μg/mL, respectively (see Figure 1.8). This trend reflects the 
difference in activity determined in the ANT(2’’)-Ia inhibition assay. However, at a 50 μM 
concentration of β-thujaplicinol all bacterial cells had died, while a considerable amount of cells 
(~80%) remained at the same concentration of 1.39. At these higher concentrations of 1.39, no 
growth was seen at the lowest concentration of gentamicin tested (2 μg/mL). Thus, the highest 
non-toxic concentrations of 1.39 were more effective at restoring antibiotic activity than the 
highest non-toxic concentrations of β-thujaplicinol. Though not directly therapeutically useful, it 
does imply that 1.39 could have advantages over β-thujaplicinol in studying ANT(2’’)-Ia 






A library of αHTs were synthesized and tested for their inhibition of ANT(2’’)-Ia. 
Several were identified as potent inhibitors, and two were found to have additional specific 
synergistic activity with gentamicin against gentamicin-resistant, ANT(2’’)-Ia-expressing E. coli. 
One of these compounds has significantly less background antibacterial activity with respect to 
E. coli than the natural product lead, β-thujaplicinol, and could have advantages in the study of 
the enzyme in cell-based assays. These results validate the oxidopyrylium 
cycloaddition/ring-opening method as a viable approach to generating new ANT(2’’)-Ia 
inhibitors, and provide some preliminary insight into the structural changes required for 
inhibitory activity and cellular efficacy. 
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1.12. Supplementary Experimental Details 
 Drs. Michael P. D’Erasmo and Christine Meck performed some of the synthetic work and 
Dr. Georgina Cox performed the biological assays for this study. All of the experimental details 
can be found in the Supporting Information for the publications on which this chapter is based.S1,S2 
This material is available free of charge at the ACS (http://pubs.acs.org) and at ScienceDirect 
(https://www.sciencedirect.com).  
 
1.12.1. General Information 
All starting materials and reagents were purchased from commercially available sources 
and used without further purification, with exception of CH2Cl2, which was purified on a solvent 
purification system prior to the reaction. 1H NMR shifts are measured using the solvent residual 
peak as the internal standard (CHCl3 δ 7.26), and reported as follows: chemical shift, multiplicity 
(s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet of doublet, q = quartet, m = 
multiplet), coupling constant (Hz), and integration. 13C NMR shifts are measured using the solvent 
residual peak as the internal standard (CDCl3 δ 77.20), and reported as chemical shifts. Infrared 
(IR) spectral bands are characterized as broad (br), strong (s), medium (m), and weak (w). 
Microwave reactions were performed via the Biotage Initiator 2.5. Purification via column 
chromatography was performed on the Biotage Isolera Prime, with Biotage SNAP 10g or 25g 






1.12.2. Synthesis and Characterization of 8-oxabicyclo[3.2.1]octenes (S1.1a-d) 
 
General Procedure. To a solution of salt 1.30aS2 and alkyne (5-10 equiv) in CHCl3 (0.5 M) was 
added N,N-diisopropylaniline (1.2 equiv). The reaction mixture was subjected to microwave 
irradiation at 100 °C for one hour. Reaction mixture was then loaded directly onto column for 
chromatography and purified. 
 
3-methoxy-5-methyl-6-(naphthalen-1-yl)-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (S1.1a). To 
a solution of salt 1.30a (108.2 mg, 0.373 mmol) and 1-ethynylnapthalene (527 μL, 
3.73 mmol) in CDCl3 (746 μL) was added N,N-diisopropylaniline (87 μL, 0.447 
mmol). After microwave irradiation at 100 °C for 60 min, the reaction mixture was 
purified by chromatography (Biotage Isolera Prime, 10 g silica gel column, solvent gradient: 5% 
EtOAc in hexanes (3 CV); 2-5% EtOAc in hexanes (8 CV); 5-10% EtOAc in hexanes (10 CV); 
10-20% EtOAc in hexanes (10 CV); 20-35% EtOAc in hexanes (8 CV)). Product fractions were 
concentrated to yield S1.1a as an orange oil (85.7 mg, 79% yield). Rf= 0.30 in 25% EtOAc in 
hexanes. IR (thin film, KBr) 3057 (w), 2978 (w), 2930 (w), 2836 (w), 1710 (s), 1605 (m) 1345 
(w), 1268 (w), 1132 (m), 1117 (w), 989 (w), 778 (w) cm-1. 1H NMR (200 MHz, CDCl3) δ 8.05 – 
7.94 (m, 1H), 7.91 – 7.67 (m, 2H), 7.58 – 7.35 (m, 3H), 7.22 (d, J = 1.2 Hz, 1H), 6.39 (d, J = 2.2 
Hz, 1H), 6.16 (s, 1H), 5.18 (d, J = 2.5 Hz, 1H), 3.67 (s, 3H), 1.51 (s, 3H). 13C NMR (100 MHz, 
CDCl3) δ 190.2 (s), 156.5 (s), 145.9 (s), 134.0 (s), 131.6 (s), 131.6 (s), 128.8 (s), 128.7 (s), 126.8 
28 
(s), 126.7 (s), 126.5 (s), 125.7 (s), 125.1 (s), 123.7 (s), 120.2 (s), 88.2 (s), 86.8 (s), 55.0 (s), 21.6 
(s).  
 
3-methoxy-5-methyl-6-(naphthalen-2-yl)-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (S1.1b). To 
a solution of salt 1.30a (17.0 mg, 0.058 mmol) and 2-ethynylnapthalene (88.9 mg, 
0.584 mmol) in CDCl3 (117 μL) was added N,N-diisopropylaniline (13.7 μL, 0.070 
mmol). After microwave irradiation at 100 °C for 60 min, the reaction mixture was 
purified by chromatography (Biotage Isolera Prime, 10 g silica gel column, solvent gradient: 5% 
EtOAc in hexanes (3 CV); 2-5% EtOAc in hexanes (8 CV); 5-10% EtOAc in hexanes (10 CV); 
10-20% EtOAc in hexanes (10 CV); 20-35% EtOAc in hexanes (8 CV)). Product fractions were 
concentrated to yield S1.1b as a yellow oil (14.4 mg, 84% yield). Rf= 0.28 in 25% EtOAc in 
hexanes. IR (thin film, KBr) 3056 (w), 2963 (w), 2933 (w), 2837 (w), 1708 (m), 1605 (w), 1174 
(w), 1344 (w), 1131 (m), 1101 (w), 867 (w), 694 (w) cm-1. 1H NMR (200 MHz, CDCl3) δ 7.89 – 
7.80 (m, 3H), 7.71 (d, J = 1.5 Hz, 1H), 7.55 – 7.48 (s, 1H), 7.44 (d, J = 1.7 Hz, 1H), 7.40 (d, J = 
1.8 Hz, 1H), 6.41 (d, J = 2.5 Hz, 1H), 6.30 (s, 1H), 5.05 (d, J = 2.5 Hz, 1H), 3.64 (s, 3H), 1.76 (s, 
3H). 13C NMR (50 MHz, CDCl3) δ 190.2 (s), 159.0 (s), 146.4 (s), 133.5 (s), 133.4 (s), 130.7 (s), 
128.9 (s), 128.5 (s), 128.1 (s), 127.1 (s), 127.0 (s), 125.0 (s), 124.4 (s), 123.7 (s), 119.5 (s), 86.8 
(s), 86.2 (s), 55.1 (s), 22.7 (s).  
 
6-(4-chlorophenyl)-3-methoxy-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (S1.1c). To a 
solution of salt 1.30a (100.0 mg, 0.344 mmol) and 1-chloro-4-ethynylbenzene (469.83 
mg, 3.44 mmol) in CHCl3 (689 μL) was added N,N-diisopropylaniline (80 μL, 0.413 
mmol). After microwave irradiation at 100 °C for 60 min, the reaction mixture was 
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purified by chromatography (Biotage Isolera Prime, 10 g silica gel column, solvent gradient: 5% 
EtOAc in hexanes (3 CV); 2-5% EtOAc in hexanes (8 CV); 5-10% EtOAc in hexanes (10 CV); 
10-20% EtOAc in hexanes (10 CV); 20-35% EtOAc in hexanes (8 CV)). Product fractions were 
concentrated to yield S1.1c as a yellow solid (37.8 mg, 40% yield). Melting Point (MP) = 138-141 
°C. Rf= 0.27 in 25% EtOAc in hexanes. IR (thin film, KBr) 3066 (w), 2974 (w), 2935 (w), 2839 
(w), 1711 (s), 1604 (m), 1490 (w), 1174 (w), 1131 (w), 1092 (w), 864 (w), 827 (w) cm-1. 1H NMR 
(200 MHz, CDCl3) δ 7.36 (d, J = 8.7 Hz, 2H), 7.21 (d, J = 8.7 Hz, 2H), 6.29 (d, J = 2.3 Hz, 1H), 
6.16 (s, 1H), 4.98 (d, J = 2.5 Hz, 1H), 3.60 (s, 3H), 1.66 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 
189.9 (s), 157.9 (s), 146.2 (s), 134.8 (s), 131.7 (s), 129.2 (s), 127.5 (s), 123.9 (s), 119.2 (s), 86.5 
(s), 85.9 (s), 55.0 (s), 22.3 (s).  
 
3-methoxy-5-methyl-6-(4-(trifluoromethyl)phenyl)-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one 
(S1.1d). To a solution of salt 1.30a (100.2 mg, 0.345 mmol) and 1-ethynyl-4-
(trifluoromethyl)benzene (563 μL, 3.45 mmol) in CDCl3 (690 μL) was added N,N-
diisopropylaniline (80 μL, 0.414 mmol). After microwave irradiation at 100 °C for 60 
min, the reaction mixture was purified by chromatography (Biotage Isolera Prime, 25 g silica gel 
column, solvent gradient: 5% EtOAc in hexanes (3 CV); 2-5% EtOAc in hexanes (8 CV); 5-10% 
EtOAc in hexanes (10 CV); 10-20% EtOAc in hexanes (10 CV); 20-35% EtOAc in hexanes (8 
CV)). Product fractions were concentrated to yield S1.1d as a yellow oil (77.6 mg, 72% yield). 
Rf= 0.30 in 25% EtOAc in hexanes. IR (thin film, KBr) 3063 (w), 2981 (w), 2938 (w), 2840 (w), 
1713 (s), 1606 (m), 1410 (w), 1327 (s), 1129 (s), 1016 (m), 865 (w), 832 (w) cm-1. 1H NMR (200 
MHz, CDCl3) δ 7.63 (d, J = 8.1 Hz, 2H), 7.38 (d, J = 8.1 Hz, 2H), 6.40 (d, J = 2.5 Hz, 1H), 6.16 
(s, 1H), 5.01 (d, J = 2.5 Hz, 1H), 3.60 (s, 1H), 1.66 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 189.7 
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(s), 157.8 (s), 146.3 (s), 136.9 (s), 130.9 (q, J = 32.8 Hz), 126.6 (s), 126.0 (q, J = 3.8 Hz), 125.9 
(s), 124.2 (q, J = 272.1 Hz), 118.9 (s), 86.6 (s), 86.2 (s), 55.1 (s), 22.3 (s).  
 
1.12.3. Synthesis and Characterization of αHTs via One-Pot TfOH/HBr/AcOH 
 
General Procedure. In a 15 mL round-bottom flask was placed a solution of 8-
oxabicyclo[3.2.1]octene S1.1 in CHCl3 (0.1 M). To the solution at rt was added 4 equivalents of 
triflic acid. The mixture was stirred for 30 minutes before quenching with an equivalent volume 
of pH 7 phosphate buffer and extracting with CH2Cl2 to isolate the methoxytropolone. To this 
compound was added HBr in AcOH (33%) at reflux for 4 hours. Reaction mixture was then 
quenched to pH 5 using a pH 7 phosphate buffer and extracted with CH2Cl2. 
 
2,7-dihydroxy-4-methyl-5-(naphthalen-1-yl)cyclohepta-2,4,6-trienone (1.57). To a solution of 
bicycle S1.1a (35.6 mg, 0.1218 mmol) in CDCl3 (1.22 mL) was added triflic 
acid (43.1 μL, 0.487 mmol). The reaction was allowed to stir for 30 minutes at 
rt before quenching to pH 7 with pH 7 phosphate buffer and extracting with CH2Cl2 (5 x 10 mL). 
Combined organics were dried over Na2SO4, filtered, and concentrated under reduced pressure. 
To the isolated methoxytropolone (18.2 mg) was added 800 μL 33% HBr/AcOH solution. The 
reaction was heated to reflux (120 °C) for 7 hours before being quenched to pH 6 with 10 mL of 
pH 7 phosphate buffer. The organic layer was isolated and the aqueous layer was extracted with 
CH2Cl2 (5 x 10 mL). Combined organics were dried over Na2SO4, filtered, and concentrated under 
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reduced pressure to yield 1.57 as a brown oil (13.4 mg, 77% yield). IR (thin film, KBr) 3248 (br), 
1526 (m), 1447 (w), 1383 (m), 1278 (w), 1239 (w), 1220 (w), 1086 (w), 783 (w), 730 (w) cm-1. 
1H NMR (200 MHz, CDCl3) δ 7.92 (dd, J = 7.8, 4.3 Hz, 2H), 7.63 (s, 1H), 7.52 (s, 1H), 7.61 – 
7.27 (m, 5H), 2.08 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 167.9 (s), 158.3 (s), 156.8 (s), 147.4 
(s), 142.1 (s), 138.9 (s), 130.9 (s), 130.6 (s), 130.3 (s), 129.2 (s), 129.1 (s), 126.0 (s), 125.7 (s), 
124.5 (s), 123.7 (s), 123.0 (s), 30.0 (s), 26.5 (s).  
 
2,7-dihydroxy-4-methyl-5-(naphthalen-2-yl)cyclohepta-2,4,6-trienone (1.58). To a solution of 
bicycle S1.1b (42.4  mg, 0.145 mmol) in CDCl3 (1.45 mL) was added triflic 
acid (51.3 μL, 0.580 mmol). The reaction was allowed to stir for 30 minutes at 
rt before quenching to pH 6 with pH 7 phosphate buffer and extracting with 
CH2Cl2 (5 x 10 mL). Combined organics were dried over Na2SO4, filtered, and concentrated under 
reduced pressure. To the isolated methoxytropolone (15.6 mg) was added 686 μL 33% HBr/AcOH 
solution. The reaction was heated to reflux (120 °C) for 8 hours before being quenched to pH 6 
with 10 mL of pH 7 phosphate buffer. The organic layer was isolated and the aqueous layer was 
extracted with CH2Cl2 (5 x 10 mL). Combined organics were dried over Na2SO4, filtered, and 
concentrated under reduced pressure to yield 1.58 as a brown oil (12.5 mg, 85% yield). IR (thin 
film, KBr) 3248 (br), 1526 (w), 1446 (w), 1392 (w), 1284 (w), 1231 (w), 1205 (w), 1122 (w), 
1092 (w), 907 (w), 858 (w) 795 (w), 730 (w) cm-1. 1H NMR (200 MHz, CDCl3) δ 7.89 (m, 3H), 
7.71 (s, 1H), 7.61 (s, 1H), 7.59 (s, 1H), 7.55 (dd, J = 2.9 Hz, 1H), 7.55 (d, J = 9.5 Hz, 1H), 7.36 
(dd, J = 8.4, 1.6 Hz, 1H), 2.29 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 167.62 (s), 158.13 (s), 
156.79 (s), 143.95 (s), 141.39 (s), 139.43 (s), 133.58 (s), 132.87 (s), 128.64 (s), 128.40 (s), 128.14 
(s), 127.52 (s), 127.06 (s), 126.87 (s), 126.76 (s), 124.59 (s), 53.75 (s), 26.82 (s).  
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4-(4-bromophenyl)-2,7-dihydroxy-5-methylcyclohepta-2,4,6-trienone (1.59). To a solution of 
previously-made 8-oxabicyclo[3.2.1]octene intermediateS3 (17.6 mg, 0.0548 
mmol) in CDCl3 (548 μL) was added triflic acid (19.4 μL, 0.219 mmol). The 
reaction was allowed to stir for 30 minutes at rt before quenching to pH 6 with 
pH 7 phosphate buffer and extracting with CH2Cl2 (5 x 10 mL). Combined organics were dried 
over Na2SO4, filtered, and concentrated under reduced pressure. To the isolated methoxytropolone 
(12.5 mg) was added 550 μL 33% HBr/AcOH solution. The reaction was heated to reflux (120 °C) 
for 4 hours before being quenched to pH 5 with 10 mL of pH 7 phosphate buffer. The organic layer 
was isolated and the aqueous layer was extracted with CH2Cl2 (5 x 10 mL). Combined organics 
were dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 1.59 as an 
orange/brown oil (10.3 mg, 86% yield). IR (thin film, KBr) 3248 (br), 1528 (m), 1487 (w), 1447 
(w), 1388 (w), 1279 (w), 1208 (w), 1128 (w), 1092 (w), 1072 (w), 1012 (w), 814 (w), 669 (w) cm-
1. 1H NMR (200 MHz, CDCl3) δ 7.58 (d, J = 6.8 Hz, 2H), 7.43 (s, 1H), 7.26 (s, 1H), 7.12 (d, J = 
8.4 Hz, 2H), 2.23 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 167.61 (s), 158.35 (s), 156.55 (s), 142.76 
(s), 142.52 (s), 139.09 (s), 132.21 (s), 130.36 (s), 124.54 (s), 124.00 (s), 122.43 (s), 26.79 (s).  
 
4-(4-chlorophenyl)-2,7-dihydroxy-5-methylcyclohepta-2,4,6-trienone (1.60). To a solution of 
bicycle S1.1c (19.2 mg, 0.0694 mmol) in CHCl3 (694 μL) was added triflic acid 
(24.5 μL, 0.278 mmol). The reaction was allowed to stir for 30 minutes at rt 
before quenching with sodium acetate (56.9 mg, 0.693 mmol). After stirring for 
an additional 15 minutes, the solution was concentrated under reduced pressure. To the mixture 
was added 696 μL AcOH and 151 μL 33% HBr/AcOH solution. The reaction was heated to 90 °C 
for 4 hours before being quenched to pH 5 with 10 mL of pH 7 phosphate buffer. The organic layer 
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was isolated and the aqueous layer was extracted with CH2Cl2 (5 x 10 mL). Combined organics 
were dried over Na2SO4, filtered, and concentrated under reduced pressure. Upon finding clean 
conversion to the methoxytropolone, the product was resubjected to the HBr/AcOH reflux 
conditions (847 μL 33% HBr/AcOH solution, 120 °C) for two hours to yield 1.60 as a black oil 
(16.5 mg, 90% yield). IR (thin film, KBr) 3066 (w), 2974 (w), 2935 (w), 2839 (w), 1711 (s), 1604 
(m), 1490 (w), 1174 (w), 1131 (w), 1092 (w), 864 (w), 827 (w) cm-1. 1H NMR (200 MHz, CDCl3) 
δ 7.56 (s, 1H), 7.43 (s, 1H), 7.42 (d, J = 8.3 Hz, 2H), 7.18 (d, J = 8.4 Hz, 2H), 2.24 (s, 3H). 13C 
NMR (100 MHz, CDCl3) δ 167.62 (s), 158.11 (s), 156.78 (s), 142.55 (s), 139.09 (s), 134.04 (s), 
130.14 (s), 129.31 (s), 124.55 (s), 124.04 (s), 29.99 (s), 26.83 (s).  
 
2,7-dihydroxy-4-methyl-5-(4-(trifluoromethyl)phenyl)cyclohepta-2,4,6-trienone (1.61). To a 
solution of bicycle S1.1d (27.3 mg, 0.0880 mmol) in CDCl3 (880 μL) was 
added triflic acid (31.1 μL, 0.352 mmol). The reaction was allowed to stir for 
30 minutes at rt before quenching to pH 7 with pH 7 phosphate buffer and 
extracting with CH2Cl2 (5 x 10 mL). Combined organics were dried over Na2SO4, filtered, and 
concentrated under reduced pressure. To the isolated methoxytropolone (10.5 mg) was added 461 
μL 33% HBr/AcOH solution. The reaction was heated to reflux (120 °C) for 7 hours before being 
quenched to pH 5 with 10 mL of pH 7 phosphate buffer. The organic layer was isolated and the 
aqueous layer was extracted with CH2Cl2 (5 x 10 mL). Combined organics were dried over 
Na2SO4, filtered, and concentrated under reduced pressure to yield 1.61 as a brown oil (6.3 mg, 
63% yield). IR (thin film, KBr) 3247 (br), 1617 (w), 1530 (m), 1392 (w), 1324 (s), 1281 (w), 
1166 (w), 1126 (m), 1068 (m), 1017 (w), 822 (w) cm-1. 1H NMR (200 MHz, CDCl3) δ 7.72 (d, J 
= 8.5 Hz, 2H), 7.58 (s, 1H), 7.41 (s, 1H), 7.38 (d, J = 8.5 Hz, 2H), 2.24 (s, 3H). 13C NMR (100 
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MHz, CDCl3) δ 167.8 (s), 158.3 (s), 156.8 (s), 147.4 (s), 142.1 (s), 138.9 (s), 130.4 (q, J = 32.7 
Hz), 129.1 (s), 126.0 (q, J = 3.7 Hz), 124.5 (s), 124.3 (q, J = 270.0 Hz) 123.7 (s), 26.7 (s).  
 
1.12.4. NMR Spectra of Synthesized Compounds 
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Chapter II  
Synthesis and Biological Assessment of 3,7-Dihydroxytropolones 
2.1. Introduction 
7-Hydroxytropolones (α-hydroxytropolones, or αHTs; 2.1a) and 3,7-dihydroxytropolones 
(3,7-dHTs, 2.1b) (Scheme 2.1A) are troponoids with three and four contiguous oxygen atoms, 
respectively, and display an extraordinarily broad range of biological activity.1 While this activity 
is most often attributed in both cases to their ability to serve as metal binding fragments for many 
physiologically relevant dinuclear metalloenzymes (2.2, Scheme 2.1A), stark differences in 
bioactivity have been observed 
between them. For example, αHTs 
appear to be substantially more 
potent than 3,7-dHTs as inhibitors of 
HIV ribonuclease H,2,3 a promising 
target for HIV antivirals that 
remains untargeted clinically, as 
well as aminoglycoside-2″-O-
nucleotidyltransferase, one of the 
most common determinants of 
enzyme-dependent aminoglycoside 
resistance in Pseudomonas 
aeruginosa.4 On the other hand, the 
3,7-dHT natural product puberulic 
acid has demonstrated potent 
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antimalarial activity, with selectivity on par with clinical agent artesunate, whereas in similar 
assays αHTs have substantially lower potency and selectivity.5 3,7-dHT also possesses activity 
against B16 melanoma cells an order of magnitude greater than αHTs, and increases the lifespan 
of mice bearing B16 melanoma comparably to mice administered the chemotherapeutic agent 
mitomycin C.6  
In order to better understand the nuances of structure-bioactivity differences between αHTs 
and 3,7-dHTs, efficient synthetic methods are needed to access both classes, and of particular value 
would be those that also allow comparable substitution.7 Recently, a galactose-based method 
previously used by Sunazuka and Omura to synthesize puberulic acid8 was further adapted to 
develop a small library of both 3,7-dHTs and αHTs (Scheme 2.1B), as well as other related 
troponoids.9 Testing of these molecules for their antimalarial activity revealed that a carboxylic 
acid was key to providing selectivity against Plasmodium falciparum K1 versus MRC-5 cells, and 
it did so whether on an αHT or a 3,7-dHT, but provided more selectivity with 3,7-dHT. These 
studies highlight the value of a divergent, unifying strategy in SAR determination of oxygenated 
troponoids, and their importance in assessing the inhibitory potential of these oxygenated 
troponoids. 
Our lab has previously reported an extremely efficient oxidopyrylium cycloaddition/ring 
opening strategy for αHT synthesis that has to date generated over 50 published αHTs with varying 
substitution patterns,10,11 and has been used to provide SAR and pursue synthetic chemistry-based 
optimization studies related to various human diseases.12-18 We herein report the adaptation of this 
route to access a series of 3,7-dHTs. We highlight this strategy through the synthesis of a potential 
biosynthetic precursor to the 3,7-dHT natural products puberulonic and puberulic acid. The 
molecules were assessed as part of biochemical and biological studies related to HIV, hepatitis B 
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virus (HBV), and herpes simplex virus (HSV)-1 and -2. These studies help provide an 
understanding of the advantages and disadvantages of 3,7-dHTs and αHTs as chemotypes for drug 
discovery and development. 
 
2.2. Synthesis of 3,7-Dihydroxytropolones 
2.2.1. Preliminary Library of 3,7-dHTs 
Our synthesis started with a cycloaddition between oxidopyrylium triflate salt 2.8a, which 
can be made on gram scale in 3 steps from commercially-available kojic acid,19 and 
iodopropiolates (Scheme 2.2A, 2.12a/b), which are prepared from the corresponding propiolates 
using silver nitrate and N-iodosuccinimide.20,21 Bromopropiolates are also capable of efficient 
oxidopyrylium cycloaddition and have been used in the synthesis of bromohydroxytropolones,14 
but their volatility and strong lachrymator properties pose technical challenges. 
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The iodobicycles can then be converted into methoxybicycles through a DMAP-catalyzed 
methanolysis (2.13a/b → 2.14a/b). These conditions were deemed necessary when we found that 
Brønsted base-mediated methanolysis led to dimethyl acetals (e.g. 2.13d), while DMAP 
incorporation was observed as the major product when chloroform was employed as the solvent 
in an attempt at hydrolysis (2.13c, Scheme 2B). Interestingly, subsequent ring-opening attempts 
on these bicycles (2.14a/b → 2.15a/b) using sulfonic acids led to formation of oxidopyrylium 
dimers as the major product, as observed by crude 1H-NMR (e.g. 2.17a, Scheme 2.2C). We 
hypothesize that this may proceed via protonation and elimination of the β-methoxyenoate 2.20, 
which would lead to a rapidly dimerizing oxidopyrylium ylide (2.8* → 2.17a).22 Fortunately, an 
alternative procedure using the Lewis acid boron trichloride promoted clean conversion to 
3,7-dimethoxytropolones 2.15a and 2.15b, which were subsequently converted to the 3,7-dHTs 
2.16a and 2.16b using hydrobromic acid in acetic acid at elevated temperatures.  
Additionally, in the presence of excess water along with extended reaction times, methyl 
ester 2.15a was readily decarboxylated (2.16c, Scheme 2.2D), which can be attributed to the 
participation of a β-keto acid tautomer. Thus, while the ester provides a convenient synthetic 
handle for efficient oxidopyrylium cycloaddition and subsequent iodide for methoxide exchange, 
it can be readily removed if desired. 
 
2.2.2. Synthetic Efforts Towards Total Synthesis of a Potential Biosynthetic Intermediate 
With an efficient method for 3,7-dHT synthesis in hand, we sought to test the new strategy 
in total synthesis. The two most widely studied 3,7-dHTs are puberulonic and puberulic acid, 
which have been isolated from the fungus Penicillum puberulum.23 These natural products are also 
close structural homologs of the 6-hydroxytropolones stipitatonic and stipitatic acid,24 the focus of 
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recent biosynthetic studies by Cox and coworkers.25 These studies demonstrated that stipitatic acid 
is formed from stipitatonic acid, which is, in turn, formed from the lactone stipitalide (2.21, 
Scheme 2.3). While a similar biosynthetic pathway seems plausible for puberulonic and puberulic 
acid, the 3,7-dHT stipitalide homolog 2.16d is unknown. Access to this molecule could be useful 
in elucidating the biosynthesis of puberulic and puberulonic acid, and our synthetic strategy 
appeared uniquely well suited for this task. Thus, we set out to conduct a total synthesis of 2.16d. 
 
We began our synthesis with the chloromethylene-containing oxidopyrylium salt 2.8b 
(Scheme 2.4). Initial attempts towards bicycle 2.13e using our prior conditions (‘a’, Scheme 2.4) 
lead to a significant amount of compound 2.13b, which created purification challenges given the 
similar polarities of 2.13b and 2.13e. We hypothesized that this product was formed through a 
hydride transfer from the N,N-diisopropylaniline,26 and thus, leveraging the readily reversible 
nature of this class of oxidopyrylium ylides (formed following deprotonation of 2.8b),10 we 
synthesized and isolated dimer 2.17b as the source of the ylide.27 Indeed, this alternative procedure 
led to the dihalogen 2.13e without any noticeable 2.13b. While this intermediate offered two 
electrophilic handles, namely a β-iodoacrylate for methanolysis and a primary alkyl chloride for 
eventual lactonization, we reasoned that the alkyl chloride would be stable to the methanolysis 
conditions because of the adjacent tertiary center. Indeed, methanolysis of 2.13e proceeded 
efficiently while maintaining the chloride’s integrity, even though higher temperatures were 
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needed for this transformation than for 2.13a/b. Subsequent ring-opening afforded 
methoxytropolone 2.15c, which was then advanced to 2.16d through a three-step acetolysis/ 
lactonization/demethylation sequence. During the course of these studies, we also discovered that 
reverse-phase chromatography of 2.15c facilitated on-column lactonization to afford 2.15e, 
providing a more direct synthetic method. 
 
2.3. Biological Studies of αHTs versus 3,7-dHTs 
2.3.1. HIV-Associated Activity  
One of the more active areas of research in our group has been αHT antiviral development, 
as several viral nucleases have been identified as targets for these molecules.2,3,13-18 The most 
widely studied in these contexts is the ribonuclease H function of HIV reverse transcriptase (HIV 
RT RNaseH),2,3,13,28-30 a promising candidate for therapeutic development that remains untargeted 
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clinically. αHTs are potent inhibitors of the enzyme with 50% inhibition concentrations (IC50) less 
than 200 nM, and several synthetic αHTs have been developed with modest antiviral activity in 
cell-based assays.2,13,29 While both 3,7-dHTs and αHTs are known inhibitors of the enzyme, and 
the collection of literature sources indicate that αHTs are superior inhibitors, head-to-head 
comparisons of both classes of molecules have not to the best of our knowledge been conducted. 
We thus tested 3,7-dHTs 2.16a–2.16d, αHT congener 2.26, and methoxytropolone congeners 
2.15a and 2.27 for their ability to inhibit HIV-1 RT RNaseH.  
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Consistent with literature trends, αHT 2.26 was the most potent of the compounds tested, with a 
4–5 fold increase over the 3,7-dHTs (Figure 2.1). Methoxytropolones were even less potent, 
consistent with tropolone activity. Furthermore, while promising cell-based HIV antiviral activity 
of 3,7-dHT has been described in the literature,3 our synthetic 3,7-dHTs showed no protective 
effects, possibly due to a combination of weaker anti-RNaseH activity and higher cytotoxicity.  
Compound 2.26, which is known to have modest HIV protective effects,13 was tested 
simultaneously as a positive control. Thus, early indications suggest that the extra hydroxyl in 
3,7-dHTs is unfavorable for HIV therapeutic development targeting RNaseH. 
 
2.3.2. HBV-Associated Activity  
Hepatitis B also has an RNase H function that has become a target for antiviral drug 
development, and αHTs have emerged as one of the most promising scaffolds.31 A 3,7-dHT has 
never been tested for this activity, and thus we assessed our new compounds’ HBV RNase 
H-specific antiviral activity by monitoring the amount of viral (+)-DNA strand versus (−)-DNA, 
since inhibiting RNase H activity suppresses production of the former. As expected, αHT 2.26 
showed only minor cytotoxicity against the host cell line, HepDES19, while selectively inhibiting 
synthesis of the viral (+)-DNA. Selective inhibition of viral (+)-DNA was also observed with 
3,7-dHTs 2.16a and 2.16b, although they were significantly more cytotoxic. It is worth noting the 
structural similarities of the two selective inhibitors, 2.16a and 2.16b, to compound 2.26 and the 
lack of activity of compound 2.16c, which could indicate an important role of the carbonyl 
appendage. Unfortunately, the EC50 values of the viral suppression of 2.16a/b coupled with their 
CC50 values revealed virtually no therapeutic window, as compared to the 60-fold window of αHT 
2.26. Thus, while these experiments demonstrate antiviral potential for 3,7-dHTs that may warrant 
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further studies, early indications suggest they are not advantageous over αHTs. On the other hand, 
the 3,7-dimethoxytropolone 2.15a displayed moderate inhibition selectivity for (+)-DNA, had an 
antiviral EC50 value of 5.5 μM, and was nontoxic at concentrations of up to 100 μM. Thus, 
3,7-dimethoxytropolone appears to be a viable chemotype for further anti-HBV development. 
 
2.3.3. HSV-associated activity  
While 3,7-dHTs had never been tested for anti-HSV activity prior to our studies, αHTs 
were identified as anti-HSV agents, with the natural product manicol displaying antiviral EC50 
values against HSV-1 and -2 of 350 nM and 580 nM, respectively.32 Furthermore, tests against 20 
synthetic αHTs synthesized through our oxidopyrylium cycloaddition/ring opening procedure 
identified a synthetic αHT with antiviral EC50 values against HSV-1 and -2 of 120 nM and 80 nM, 
respectively (see 2.28, Figure 2.3).15 In all cases, cytotoxicity was not observed against Vero cells 
within the 24 hours experiment. We thus tested our library of tropolones and found that 3,7-dHTs 
2.16a, 2.16b, and 2.16c all strongly inhibited replication of HSV-1 at a concentration of 5 μM, 
with suppression levels comparable to the therapeutic anti-HSV agent acyclovir (ACV) and 
exceeding that of cidofovir (CDV) (Figure 2.2A). αHT 2.26 only showed moderate replication 
inhibition at 5 μM, and no activity at 1 μM, whereas the activity for 2.16a–2.16c was maintained. 
Methoxytropolones 2.15a and 2.27 were the least active compounds among the series tested. 
3,7-dHT 2.16d was inactive, illustrating how changes in the side-chains can impact activity. 
3,7-dHTs 2.16a–c inhibited HSV-2 replication with comparable suppression levels and potencies, 
and this activity was maintained against three other HSV-2 clinical isolates at 5 μM (Figure 2.2B). 
The EC50 values of compounds 2.16a and 2.16c were comparable to ACV for HSV-1, and showed 
no cytotoxicity versus the Vero cell line at up to 100 μM for 24 hours (Figure 2.2C). Furthermore, 
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while ACV was nearly an order of magnitude less potent against HSV-2 than HSV-1, 2.16a and 
2.16c maintained significant potency. 
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2.3.4. Mechanistic Insights on Mode of Action 
Although the mechanism of action is currently under investigation, experiments with 2.16a 
against the ACV-resistant TK-HSV-1 and HSV-2 strains confirmed a different mechanism of 
action than ACV (Figure 2.2B). One hypothesis is that the molecules could engage one or more 
viral nucleotidyltransferases.33 For example, the HSV-1 DNA packing terminase pUL15 encodes 
a C-terminal nuclease activity that can be inhibited by αHTs.14,34 Thus, we tested 3,7-dHTs against 
recombinant pUL15C and found them to be inhibitors of the enzyme, but with less potency than 
αHT 2.26 (Figure 2.2C). 
Given the SAR suggesting benefits of the additional oxygen for HSV inhibition potency, a 
3,7-dHT analog of the most potent anti-HSV αHT described to date, compound 2.28, was 
synthesized (2.16e, Scheme 2.5). 
 
Anti-HSV-1 activity was assessed in parallel with 3,7-dHT 2.16a and αHTs 2.28 and 2.26 (Figure 
2.3B). As expected, compound 2.26 showed no antiviral activity, even at 5 μM, whereas some 
viral suppression was observed for 2.28, 2.16a and 2.16e. At 1 μM, 2.16e and 2.28 antiviral activity 
remained at a maximum, but activity of 2.16a began to drop. At 200 nM, 2.16a was inactive, and 
both 2.28 and 2.16e began to lose some activity. EC50 values of 2.16e were ∼50 nM against both 
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HSV-1 and -2, which is the most potent anti-HSV activity of a tropolone we have found to date. 
Unfortunately, moderate cytotoxicity of 2.16e was also observed. 
 
While increases in potency against HSV were anticipated through additive effects, 
surprising effects were observed with pUL15 inhibition. While both a change from an αHT to a 
3,7-dHT (2.26 → 2.16a), and from a methyl ester to a biphenyl ketone (2.26 → 2.28) resulted in 
a decrease in pUL15 potency, changing both provided an increase in potency (2.26 → 2.16e). One 
hypothesis for this change is that the added hydroxyl permits the biphenyl side chain to adopt a 
new configuration that would promote new favorable contacts (Figure 2.4A vs. B). In silico 
modelling was thus carried out by superimposing the active site of the crystal structure of pUL15C 
(PDB id 4IOX)34 to the active site of the crystal structure of HIV RT RNase H bound to manganese 
cations and β-thujaplicinol (PDB id 3K2P).35 All computational work was performed by Prof. 
Emilio Gallicchio and Rajat Pal. The resulting structure of pUL15C was refined by energy 
minimization and simulated annealing using the Impact molecular modeling program.36 The 
receptor grid was generated using the default parameters available in the Schrodinger Suite 2016-
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3 with one special adjustment where metal constraints were applied to allow metal–ligand 
interaction at the binding site. Glide docking37 were performed with the ligands αHT 2.28 and 
3,7-dHT 2.16e. Several binding poses were obtained for the molecule 2.16e, out of which the best 
binding pose is shown in Figure 2.4.  
This conformation reveals favorable π–cation interaction between the quaternary 
ammonium cation of Lys 640 and the phenyl ring π system of the biphenyl group of the ligand. 
The biphenyl group is thought to be further stabilized by accommodating within a hydrophobic 
groove formed between Lys 640 and Asn 583 with possible hydrophobic interaction with the Leu 
636 present inside the groove. Further stabilization could also be achieved through interactions of 
the biaryl side chain with Asn 583 through NH–π interactions. These interactions are never 
observed in in silico modelling with 2.28. While further studies are needed to understand the 
specific mechanism of this increase in activity, these analyses highlight the consequences of the 
additional binding modes allowed by 3,7-dHTs, which might also result in greater likelihood of 





We have developed an oxidopyrylium cycloaddition/ring opening approach for the 
synthesis of 3,7-dHTs. This strategy was applied in the synthesis of a prospective biosynthetic 
precursor to the natural products puberulonic and puberulic acid. Finally, the new 3,7-dHTs were 
tested for antiviral activity against HIV, HBV and HSV. Through these studies we found that 
3,7-dHTs are weaker inhibitors than αHTs against HIV RNaseH, revealed 3,7-dimethoxytropolone 
as a promising chemotype for HBV-based antiviral development, and demonstrated that 3,7-dHTs 
can have greater potency against HSV than analogous αHTs. Furthermore, enzymatic inhibition 
studies coupled with preliminary in silico modelling highlight how additional configurations of 
3,7-dHTs may manifest themselves in unexpected potency increases, and could also be responsible 
for observed cytotoxicity increases. 
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2.6. Supplementary Experimental Details 
 Daniel Schiavone performed some of the synthetic work described in this study. The 
biological assays were performed by the Morrison, Tavis, Beutler, and Le Grice labs. Homology 
docking studies were carried out by Rajat Pal and Prof. Emilio Gallicchio. All of these 
experimental details can be found in the Supporting Information for the publication on which this 
chapter is based.S1 This material is provided free of charge by the RSC (http:// http://pubs.rsc.org/). 
 
2.6.1. General Information 
All starting materials and reagents were purchased from commercially available sources 
and used without further purification, with exception of CH2Cl2, which was purified on a solvent 
purification system prior to the reaction. 1H NMR shifts are measured using the solvent residual 
peak as the internal standard (CHCl3 δ 7.26, CD3OD δ 3.31, (CD3)2SO δ 2.50), and reported as 
follows: chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = 
doublet of doublet, q = quartet, m = multiplet), coupling constant (Hz), and integration. 13C NMR 
shifts are measured using the solvent residual peak as the internal standard (CDCl3 δ 77.2, CD3OD 
δ 49.0, (CD3)2SO δ 39.5), and reported as chemical shifts. Infrared (IR) spectral bands are 
characterized as broad (br), strong (s), medium (m), and weak (w). Microwave reactions were 
performed via the Biotage Initiator 2.5. Purification via normal phase column chromatography was 
performed on the Biotage Isolera Prime, with Biotage SNAP 10 g or 25 g cartridges, in a solvent 
system of ethyl acetate and hexanes. Reverse phase chromatography was performed on the Biotage 
Isolera Prime with Biotage SNAP C18 12 g cartridges, in a solvent system of water and acetonitrile 
with a 0.05% trifluoroacetic acid additive. Column gradients are measured in terms of column 
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volumes (CV). Mass spectra were recorded on a spectrometer by the electrospray ionization (ESI) 
technique with a time-of-flight (TOF) mass analyzer.   
 
2.6.2. Synthesis and Characterization of Iodobicycles (2.13a, 2.13b, 2.13e) 
General Procedure A. To a solution of salt 2.8aS2 and alkyne (10 equiv) in CH2Cl2 (0.5 
M) was added N,N-diisopropylaniline (1.2 equiv). The reaction mixture was subjected to 
microwave irradiation at 120 °C for 20 minutes. The reaction mixture was then loaded directly 
onto column for chromatography and purified. 
General Procedure B. To a solution of dimer 2.17bS2 in CH2Cl2 (0.5 M) was added alkyne 
(20 equiv). The reaction was subjected to microwave irradiation at 100 °C for one hour. The 




Procedure A: To a solution of salt 2.8a (185.0 mg, 0.6373 mmol) and methyl 3-iodopropiolate3 
(1.3365 g, 6.3734 mmol) in CH2Cl2 (2 mL) was added N,N-diisopropylaniline (148.8 
μL, 0.7649 mmol). After microwave irradiation at 120 °C for 20 min, the reaction 
mixture was purified by chromatography (Biotage Isolera Prime, 25 g silica gel column, solvent 
gradient: 5% EtOAc in hexanes (3 CV); 5-10% EtOAc in hexanes (8 CV); 10-15% EtOAc in 
hexanes (10 CV); 15-20% EtOAc in hexanes (10 CV); 20-25% EtOAc in hexanes (10 CV); 25-
35% EtOAc in hexanes (8 CV)). Product fractions were concentrated to yield 2.13a as a yellow 
solid (126.2 mg, 57% yield). Melting point (mp) = 132-135 °C. Rf = 0.25 in 25% EtOAc in 
hexanes. IR (thin film, KBr) 2953 (w), 2840 (w), 1711 (s), 1610 (m), 1436 (w), 1379 (w), 1311 
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(m), 1205 (m), 1121 (w), 860 (w), 693 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.06 (s, 1H), 5.03 
(s, 1H), 3.84 (s, 3H), 3.55 (s, 3H), 1.75 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 186.9 (s), 163.0 
(s), 151.0 (s), 145.1 (s), 119.2 (s), 103.4 (s), 93.8 (s), 88.0 (s), 54.9 (s), 52.3 (s), 21.8 (s). HRMS 
(ESI+) m/z calc’d for C11H12IO5




Procedure A: To a solution of salt 2.8a (12.47 mg, 0.0430 mmol) and ethyl 3-iodopropiolateS3 
(0.0963 g, 0.430 mmol) in CH2Cl2 (0.2 mL) was added N,N-diisopropylaniline (10.03 
μL, 0.0516 mmol). After microwave irradiation at 120 °C for 20 min, the reaction 
mixture was purified by chromatography (Biotage Isolera Prime, 10 g silica gel column, solvent 
gradient: 5% EtOAc in hexanes (3 CV); 5-10% EtOAc in hexanes (8 CV); 10-15% EtOAc in 
hexanes (10 CV); 15-20% EtOAc in hexanes (10 CV); 20-25% EtOAc in hexanes (10 CV); 25-
35% EtOAc in hexanes (8 CV)). Product fractions were concentrated to yield 2.13b as a yellow 
oil (15.3 mg, 98% yield). Rf= 0.29 in 25% EtOAc in hexanes. IR (thin film, KBr) 2981 (w), 2936 
(w), 1710 (s), 1609 (m), 1448 (w), 1324 (w), 1307 (w), 1259 (m), 1122 (w), 869 (w), 693 (m) cm-
1.  1H NMR (200 MHz, CDCl3) δ 6.02 (s, 1H), 4.96 (s, 1H), 4.24 (q, J = 11.1 Hz, 2H), 3.50 (s, 
3H), 1.70 (s, 3H), 1.32 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 187.0 (s), 162.6 (s), 
150.9 (s), 145.1 (s), 119.3 (s), 103.0 (s), 93.7 (s), 88.0 (s), 61.7 (s), 55.0 (s), 21.7 (s), 14.3 (s). 
HRMS (ESI+) m/z calc’d for C12H14IO5




carboxylate (2.13c). Procedure B: To a solution of dimer 2.17b (369.4 mg, 1.06 
mmol) in CH2Cl2 (2.12 mL) was added ethyl 3-iodopropiolate
3 (4.86 g, 21.7 
mmol). After microwave irradiation at 100 °C for one hour, the reaction mixture was purified by 
chromatography (Biotage Isolera Prime, 50 g silica gel column, solvent gradient: 5% EtOAc in 
hexanes (3 CV); 5-10% EtOAc in hexanes (10 CV); 10-20% EtOAc in hexanes (10 CV); 20-
35% EtOAc in hexanes (8 CV)). Product fractions were concentrated to yield 2.13c as a yellow 
oil (596.0 mg, 71% yield). Rf = 0.32 in 25% EtOAc in hexanes. IR (thin film, KBr) 2980 (w), 
2936 (w), 2839 (w), 1713 (s), 1613 (s), 1453 (w), 1369 (w), 1311 (m), 1270 (m), 1130 (w), 834 
(w), 639 (m) cm-1. 1H NMR (200 MHz, CDCl3) δ 5.99 (s, 1H), 5.13 (s, 1H), 4.44 – 4.22 (m, 
2H), 4.26 – 4.00 (dd, 2H), 3.59 (s, 3H), 1.38 (t, J = 7.1 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 
186.1 (s), 162.1 (s), 148.0 (s), 146.1 (s), 114.6 (s), 103.6 (s), 93.8 (s), 89.9 (s), 62.1 (s), 55.2 (s), 
44.7 (s), 14.3 (s). HRMS (ESI+) m/z calc’d for C12H12ClINaO5
+: 420.9310. Found: 420.9314. 
 




Procedure: To a solution of bicycle 2.13a (8.6 mg, 0.025 mmol) in methanol (1.23 
mL) was added 4-dimethylaminopyridine (3.0 mg, 0.025 mmol). After microwave 
irradiation at 120°C for 20 min, the reaction mixture was concentrated under 
reduced pressure, taken up in CH2Cl2 and purified by chromatography (Biotage Isolera Prime, 10 
g silica gel column, solvent gradient: 5% EtOAc in hexanes (3 CV); 5-35% EtOAc in hexanes (40 
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CV)). Product fractions were concentrated to yield 2.14a as a clear oil (5.8 mg, 94% yield). Melting 
point (mp) = 138-141 °C. Rf= 0.19 in 25% EtOAc in hexanes. IR (thin film, KBr) 2953 (w), 1696 
(s), 1635 (s), 1606 (s), 1449 (w), 1371 (m), 1209 (m), 1112 (s), 834 (w), 723 (m) cm-1. 1H NMR 
(200 MHz, CDCl3) δ 6.20 (s, 1H), 5.05 (s, 1H), 3.96 (s, 3H), 3.76 (s, 3H), 3.56 (s, 3H), 1.75 (s, 
3H). 13C NMR (100 MHz, CDCl3) δ 188.8 (s), 168.7 (s), 163.8 (s), 145.1 (s), 121.8 (s), 114.2 (s), 
86.0 (s), 83.4 (s), 60.7 (s), 54.9 (s), 51.7 (s), 23.0 (s). HRMS (ESI+) m/z calc’d for C12H15O6
+: 




Procedure: To a solution of bicycle 2.13b (155.1 mg, 0.4259 mmol) in methanol (12 mL) was 
added 4-dimethylaminopyridine (139.5 mg, 1.142 mmol). After microwave 
irradiation at 120 °C for 20 min, the reaction mixture was purified by 
chromatography (Biotage Isolera Prime, 10 g silica gel column, solvent gradient: 
5% EtOAc in hexanes (3 CV); 5-35% EtOAc in hexanes (35 CV)). Product fractions were 
concentrated to yield 2.14b as a clear oil (73.85 mg, 64% yield). Melting point (mp) = 84-86 °C. 
Rf = 0.48 in 50% EtOAc in hexanes. IR (thin film, KBr) 2937 (w), 1709 (s), 1692 (s), 1635 (m), 
1604 (m), 1451 (w), 1352 (w), 1241 (w), 1132 (w), 1112 (w), 986 (m), 723 (w) cm-1. 1H NMR 
(200 MHz, CDCl3) δ 6.20 (s, 1H), 5.04 (s, 1H), 4.23 (q, J = 7.1 Hz, 2H), 3.97 (s, 1H), 3.58 (s, 
1H), 1.75 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 188.7 (s), 168.2 (s), 
163.2 (s), 144.9 (s), 121.7 (s), 114.2 (s), 85.8 (s), 83.3 (s), 60.5 (s), 60.4 (s), 54.7 (s), 22.9 (s), 14.3 
(s). HRMS (ESI+) m/z calc’d for C13H17O6




carboxylate (2.14c).  
Procedure: To a solution of bicycle 2.13c (348.9 mg, 0.8753 mmol) in methanol (43 mL) was 
added 4-dimethylaminopyridine (106.9 mg, 0.8753 mmol) in a sealed tube. 
After heating at 150 °C for 20 min in a silicon oil bath, the reaction mixture 
was purified by chromatography (Biotage Isolera Prime, 25 g silica gel column, 
solvent gradient: 5% EtOAc in hexanes (3 CV); 5-35% EtOAc in hexanes (30 CV)). Product 
fractions were concentrated to yield 2.14c as a clear oil (161.1 mg, 61% yield). Rf = 0.24 in 25% 
EtOAc in hexanes. IR (thin film, KBr) 2980 (w), 1714 (s), 1690 (m), 1637 (m), 1607 (m), 1464 
(w), 1380 (w), 1224 (m), 1133 (m), 1072 (w), 983 (w), 725 (w) cm-1. 1H NMR (400 MHz, CDCl3) 
δ 6.13 (s, 1H), 5.11 (s, 1H), 4.21 (qd, J = 7.1, 2.8 Hz, 2H), 4.14 – 4.05 (m, 2H), 3.98 (s, 3H), 3.57 
(s, 3H), 1.28 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 188.0 (s), 168.7 (s), 162.9 (s), 
146.2 (s), 117.3 (s), 111.8 (s), 87.9 (s), 83.6 (s), 61.0 (s), 60.9 (s), 55.2 (s), 46.3 (s), 14.5 (s). HRMS 
(ESI+) m/z calc’d for C13H16ClO6
+: 303.0630. Found: 303.0634. 
 








Procedure: To a solution of bicyclic compound 2.14a (6.0 mg, 0.0236 mmol) 
in CH2Cl2 (1.69 mL) was added a 1M solution of BCl3 in CH2Cl2 (165.2 μL, 
0.1652 mmol). The reaction was allowed to stir at room temperature for 10 
minutes before being quenched to pH 7 with pH 7 phosphate buffer. The organic layer was isolated 
and the aqueous layer was extracted with CH2Cl2 (5 x 10 mL). Combined organics were dried over 
Na2SO4, filtered, and concentrated under reduced pressure to yield 2.15a as a red solid (5.8 mg, 
97% yield). Melting point (mp) = 93-97 °C. IR (thin film, KBr) 3192 (br), 2950 (w), 1734 (m), 
1554 (w), 1459 (w), 1329 (s), 1268 (s), 1217 (s), 1138 (m), 1078 (w), 923 (w), 796 (w). 1H NMR 
(400 MHz, CDCl3) δ 6.89 (s, 1H), 3.98 (s, 3H), 3.95 (s, 3H), 3.93 (s, 3H), 2.37 (s, 3H). 
13C NMR 
(100 MHz, CDCl3) δ 168.6 (s), 167.7 (s), 158.3 (s), 155.2 (s), 150.1 (s), 134.0 (s), 131.1 (s), 119.5 






Procedure: To a solution of bicyclic compound 2.14b (20.9 mg, 0.0780 mmol) in CH2Cl2 (5.6 
mL) was added a 1M solution of BCl3 in CH2Cl2 (546 μL, 0.546 mmol). The 
reaction was allowed to stir at room temperature for 10 minutes before being 
quenched to pH 7 with pH 7 phosphate buffer. The organic layer was isolated 
and the aqueous layer was extracted with CH2Cl2 (5 x 10 mL). Combined organics were dried over 
Na2SO4, filtered, and concentrated under reduced pressure to yield 2.15b as a yellow oil (16.9 mg, 
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81% yield). IR (thin film, KBr) 3734 (w), 2940 (w), 1731 (s), 1553 (s), 1454 (w), 1328 (m), 1267 
(m), 1217 (s), 1138 (s), 1017 (w), 901 (w), 669 (s). 1H NMR (200 MHz, CDCl3) δ 6.89 (s, 1H), 
4.41 (q, J = 7.1 Hz, 2H), 3.98 (s, 3H), 3.96 (s, 3H), 2.39 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H). 13C NMR 
(100 MHz, CDCl3) δ 168.3 (s), 167.0 (s), 158.0 (s), 155.1 (s), 149.9 (s), 134.1 (s), 130.9 (s), 119.3 
(s), 61.8 (s), 61.2 (s), 56.6 (s), 24.6 (s), 14.2 (s). HRMS (ESI+) m/z calc’d for C13H17O6
+: 




Procedure: To a solution of 1M BCl3 in CH2Cl2 (80.6 μL, 0.0806 mmol) was added a solution of 
bicyclic compound 2.14c (6.1 mg, 0.0202 mmol) in CH2Cl2 (2.88 mL) at 0 °C. 
After stirring for 6 minutes, the reaction was slowly added to 6 mL of pH 5 
phosphate buffer in a separatory funnel. After shaking, the pH of the aqueous layer was further 
adjusted to pH 4 via the gradual addition of an additional 12 mL of pH 5 phosphate buffer. The 
organic layer was isolated and the aqueous layer was extracted with CH2Cl2 (5 x 5 mL). Combined 
organics were dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 2.15c 
as a brown oil (4.7 mg, 77% yield) which was immediately taken on to the next step. IR (thin 
film, KBr) 2924 (w), 2851 (w), 1731 (s), 1558 (m), 1464 (w), 1335 (m), 1268 (s), 1218 (m), 1135 
(w), 1047 (w), 941 (w), 669 (w). 1H NMR (400 MHz, CDCl3) δ 7.07 (s, 1H), 4.48 (s, 2H), 4.45 
(q, J = 7.2 Hz, 2H), 4.04 (s, 3H), 3.98 (s, 3H), 1.42 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, 
CDCl3) δ 169.4 (s), 166.0 (s), 158.7 (s), 155.8 (s), 149.0 (s), 134.7 (s), 129.1 (s), 117.6 (s), 62.4 







Procedure: To a solution of dimethoxytropolone 2.15c (16.8 mg, 0.055 mmol) in acetic acid (5.55 
mL) was added sodium acetate (91.05 mg, 1.11 mmol). The reaction was 
allowed to stir at room temperature for 15 hours before being quenched to pH 3 
with pH 7 phosphate buffer. The organic layer was isolated and the aqueous 
layer was extracted with CH2Cl2 (5 x 10 mL). Combined organics were dried over Na2SO4, filtered, 
and concentrated under reduced pressure to yield 2.15d as a brown/yellow oil (14.7 mg, 93% 
yield). IR (thin film, KBr) 3734 (w), 2950 (br), 1737 (s), 1558 (w), 1462 (w), 1366 (w), 1333 
(w), 1221 (s), 1139 (w), 1073 (w), 669 (w). 1H NMR (400 MHz, CDCl3) δ 7.14 (s, 1H), 5.03 (s, 
2H), 4.43 (q, J = 7.1 Hz, 2H), 4.02 (s, 3H), 3.98 (s, 3H), 2.12 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H). 13C 
NMR (100 MHz, CDCl3) δ 170.6 (s), 168.8 (s), 166.2 (s), 158.4 (s), 156.8 (s), 149.8 (s), 135.2 
(s), 128.2 (s), 118.0 (s), 66.9 (s), 62.4 (s), 61.5 (s), 57.0 (s), 21.0 (s), 14.3 (s). HRMS (ESI+) m/z 
calc’d for C15H18NaO8
+: 349.0894. Found: 349.0898. 
 
7-Hydroxy-5,8-dimethoxy-1H-cyclohepta[c]furan-1,6(3H)-dione (2.15e).  
Procedure A: A solution of dimethoxytropolone 2.15d (12.9 mg, 0.034 mmol) in 2N aqueous 
NaOH (4.78 mL) was allowed to stir at room temperature for 3 hours before 
being diluted with 10 mL of CH2Cl2 and quenched to pH 3 with pH 3 phosphate 
buffer. The organic layer was isolated and the aqueous layer was extracted with 
CH2Cl2 (5 x 10 mL). Combined organics were dried over Na2SO4, filtered, and concentrated under 
reduced pressure to yield 2.15e as a yellow solid (9.1 mg, 81% yield).  
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Procedure B: Dimethoxytropolone 2.15c (4.6 mg, 0.015 mmol) was subjected to reverse phase 
column chromatography conditions (Biotage Isolera Prime, SNAP 12g C18 silica gel column, 
solvent gradient: 5% acetonitrile in water (3 CV); 5-100% acetonitrile in water (35 CV); 
acetonitrile and water each contained 0.05% TFA). Product fractions were concentrated to yield 
2.15e as a yellow solid (2.9 mg, 81% yield). Melting point (mp) = 180-184 °C. Rf= 0.36 in 10% 
methanol in dichloromethane. IR (thin film, KBr) 3734 (w), 3217 (br), 2945 (w), 1760 (s), 1573 
(s), 1457 (w), 1338 (m), 1284 (m), 1122 (w), 1051 (s), 868 (w), 668 (s). 1H NMR (400 MHz, 
CDCl3) δ 6.83 (s, 1H), 5.17 (s, 2H), 4.11 (s, 3H), 4.09 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 
171.7 (s), 168.5 (s), 162.4 (s), 154.7 (s), 149.6 (s), 144.6 (s), 119.2 (s), 106.6 (s), 69.8 (s), 62.1 (s), 
57.4 (s). HRMS (ESI+) m/z calc’d for C11H11O6
+: 239.0550. Found: 239.0558.  
 
2.6.5. Synthesis and Characterization of α-Methoxytropolone via TfOH 
 
Methyl 6-hydroxy-4-methoxy-2-methyl-5-oxocyclohepta-1,3,6-triene-1-carboxylate (2.27). 
To a solution of methyl 3-methoxy-5-methyl-2-oxo-8-oxabicyclo[3.2.1]octa-
3,6-diene-6-carboxylateS4 (484 mg, 2.16 mmol) in CH2Cl2 (22 mL) was added 
triflic acid (763 μL, 8.65 mmol). The reaction was allowed to stir for 30 min at 
rt before quenching with pH 7 phosphate buffer. The reaction mixture was then extracted with 
CH2Cl2 (3 x 20 mL), and the combined organics were dried over Na2SO4, filtered, and concentrated 
under reduced pressure to yield 2.27 as a brown solid (377 mg, 78% yield). Product can be further 
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purified via crystallization in MeOH to yield a yellow solid (233 mg, 48% yield). Melting point 
(mp) = 168-171 °C. IR (thin film, KBr) 3251 (br), 2918 (w), 2848 (w), 1717 (s), 1554 (m), 1483 
(w), 1457 (m), 1335 (s), 1297 (m), 1220 (s), 1139 (w), 1053 (s), 907 (w), 788 (m) cm-1. 1H NMR 
(400 MHz, CDCl3) δ 7.56 (s, 1H), 6.99 (s, 1H), 3.99 (s, 3H), 3.89 (s, 3H), 2.53 (s, 3H). 
13C NMR 
(100 MHz, CDCl3) δ 171.0, 169.1, 159.6, 158.3, 137.4, 131.5, 121.5, 117.4, 56.6, 52.9, 26.0. 
HRMS (ESI+) m/z calc’d for C11H13O5
+: 225.0757. Found: 225.0753. 
 
2.6.6. Synthesis and Characterization of 3,7-Dihydroxytropolones 
 
Methyl 4,6,7-trihydroxy-2-methyl-5-oxocyclohepta-1,3,6-triene-1-carboxylate (2.16a).  
Procedure: To dimethoxytropolone 2.15a (3.3 mg, 0.0130 mmol) was added 145 μL of 33% 
HBr/AcOH. The reaction was heated to reflux at 120 °C for 35 minutes before 
being quenched to pH 4 with pH 7 phosphate buffer. The organic layer was 
isolated and the aqueous later was extracted with CH2Cl2 (5 x 10 mL). Combined 
organics were dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 2.16a 
as a red/brown solid (1.6 mg, 55%). Melting point (mp) = 131-135 °C. IR (thin film, KBr) 3198 
(br), 2925 (w), 1733 (s), 1586 (w), 1525 (m), 1431 (s), 1325 (s), 1201 (s), 1057 (w), 878 (w), 796 
(w). 1H NMR (400 MHz, CD3OD) δ 7.00 (s, 1H), 3.91 (s, 3H), 2.32 (s, 3H). 
13C NMR (100 MHz, 
CDCl3) δ 167.2 (s), 157.3 (s), 154.5 (s), 153.4 (s), 152.3 (s), 136.8 (s), 125.0 (s), 120.8 (s), 52.1 
(s), 24.7 (s). HRMS (ESI+) m/z calc’d for C10H11O6
+: 227.0550. Found: 227.0556.  
 
72 
Ethyl 4,6,7-trihydroxy-2-methyl-5-oxocyclohepta-1,3,6-triene-1-carboxylate (2.16b). 
Procedure: To dimethoxytropolone 2.15b (15.5 mg, 0.0578 mmol) was added 682 μL of 33% 
HBr/AcOH in a sealed 0.5-2.0 mL sealed microwave vessel. The reaction was 
heated to reflux at 120 °C for 45 minutes in a silicon oil bath before being 
quenched to pH 4 with pH 7 phosphate buffer. The organic layer was isolated and the aqueous 
later was extracted with CH2Cl2 (5 x 10 mL). Combined organics were dried over Na2SO4, filtered, 
and concentrated under reduced pressure to yield 2.16b as a red/brown oil (12.0 mg, 87%). IR 
(thin film, KBr) 3210 (br), 2929 (w), 1730 (s), 1581 (w), 1445 (w), 1326 (w), 1193 (s), 1056 (m), 
1012 (w), 860 (w), 779 (w) cm-1. 1H NMR (400 MHz, CD3OD) δ 7.02 (s, 1H), 4.39 (q, J = 6.8 
Hz, 2H), 2.33 (s, 3H), 1.37 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CD3OD) δ 169.3 (s), 158.7 
(s), 157.5 (s), 157.4 (s), 153.2 (s), 137.0 (s), 126.9 (s), 121.0 (s), 62.8 (s), 24.4 (s), 14.4 (s). HRMS 
(ESI+) m/z calc’d for C11H12NaO6
+: 263.0526. Found: 263.0528. 
 
2,3,7-Trihydroxy-5-methylcyclohepta-2,4,6-trien-1-one (2.16c).  
Procedure: To dimethoxytropolone 2.15a (6.5 mg, 0.0256 mmol) was added 4.6 μL (10 equiv.) 
of water and 284 μL of 33% HBr/AcOH in a sealed 0.5-2.0 mL sealed microwave vessel. The 
reaction was heated to reflux at 120 °C for 35 minutes. The membrane of the sealed 
vessel was punctured with an 18G needle to release gas buildup approximately 10 
minutes after subjecting reaction to heat. Upon completion, the reaction was quenched to pH 4 
with pH 7 phosphate buffer. The organic layer was isolated and the aqueous later was extracted 
with CH2Cl2 (5 x 10 mL). Combined organics were dried over Na2SO4, filtered, and concentrated 
under reduced pressure to yield 2.16c as a red/brown oil (1.8 mg, 42%). IR (thin film, KBr) 3509 
(br), 3218 (br), 2918 (m), 1591 (w), 1517 (m), 1434 (s), 1394 (w), 1339 (w), 1199 (s), 1092 (m), 
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1068 (w), 668 (m) cm-1. 1H NMR (400 MHz, CD3OD) δ 7.01 (s, 2H), 2.40 (s, 3H). 
13C NMR 
(100 MHz, CD3OD) δ 158.2 (s), 156.6 (s), 141.2 (s), 120.3 (s), 27.0 (s). HRMS (ESI+) m/z calc’d 
for C8H9O4
+: 169.0495. Found: 169.0492. 
 
5,7,8-Trihydroxy-1H-cyclohepta[c]furan-1,6(3H)-dione (2.16d).  
Procedure: To dimethoxytropolone 2.15e (10.0 mg, 0.042 mmol) was added 453 μL of 33% 
HBr/AcOH in a sealed 0.5-2.0 mL sealed microwave vessel. The reaction was 
heated to reflux in a silicon oil bath at 120 °C for 30 minutes before being 
quenched to pH 1.5 with pH 5 phosphate buffer. The organic layer was isolated 
and the aqueous layer was extracted with CH2Cl2 (3 x 2 mL). Combined organics were dried over 
Na2SO4, filtered, and concentrated under reduced pressure to yield 2.16d as a yellow solid (5.0 
mg, 57%). IR (thin film, KBr) 3502 (br), 3215 (br), 2962 (w), 2918 (s), 2849 (m), 1747 (m), 1622 
(w), 1517 (w), 1260 (s), 1096 (m), 1022 (s), 799 (s) cm-1. 1H NMR (400 MHz, DMSO-d6) δ 6.83 
(s, 1H), 5.17 (s, 2H). 13C NMR (150 MHz, DMSO-d6) δ 171.0 (s), 164.7 (s), 159.9 (s), 154.3 (s), 
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Studies on Configurational Stability of Troplone-Amide Aryl-CO Bonds 
 
3.1 Introduction  
A fundamental goal of drug discovery is to develop 
safe and effective compounds with specificity towards their 
intended disease targets. In order to achieve this objective, it 
is crucial to consider the three-dimensional properties of 
drugs. One such characteristic is the handedness, or chirality, 
of a molecule since different spatial orientations of drugs with 
identical connectivity can have drastically differing effects in 
the body. While chirality is typically thought of in terms of 
asymmetry about a single atom or point, axial chirality 
(Figure 3.1) is a critically understudied form of chirality in 
which the spatial arrangement of substituents about an axis 
renders the molecule non-superimposable on its mirror image.1 Atropisomerism arises from restricted 
rotation about this axis, thus allowing for isolatable enantiomers. This type of isomerism is often 
exemplified by the biaryl scaffold where restricted rotation about the stereogenic CAr-CAr axis is 
responsible for the presence of enantiomers (Figure 3.1C). Separable atropisomers can generally be 
observed if the energetic barrier to rotation (ΔG‡) about the chiral axis is > 22 kcal/mol, 
corresponding to a half-life to racemization of >1000 seconds at room temperature.2 It is an issue of 
current interest in the development of ligands,3 molecular devices,4 and pharmaceutical drugs.5  
Atropisomerism is perhaps most widely appreciated within the field of synthetic organic 
chemistry as the source of chirality in numerous chiral biaryl ligands for asymmetric catalysis. 
Axially chiral bidentate ligands, such as BINAP, are most famously recognized for their use in 
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Noyori’s asymmetric hydrogenation work on olefins and carbonyls (Figure 3.2A) for which he 
was awarded the 2001 Nobel Prize.6 BINAP ligands have also been used extensively in 
atropselective cross-couplings.7 The importance of atropisomerism can also be found in other areas 
such as unidirectional molecular devices8 and switches,9 the development of which won Feringa 
the 2016 Nobel Prize (Figure 3.2B). 
 
 
While numerous axially chiral drugs are commercially available, many exist as rapidly 
interconverting atropisomers with only one enantiomer possessing the desired activity.10 
Single-enantiomer drugs have long been considered of paramount importance; perhaps most 
infamously, the antiemetic racemate thalidomide caused devastating birth defects in more than 
10,000 babies in the 1950s owing to toxicity associated with the (S)-enantiomer as well as facile in 
vivo racemization.11 Consequently, the development of efficient synthetic strategies to access single 
enantiomers is a major theme of modern synthetic organic chemistry.  
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The thalidomide tragedy was not a standalone incident. Enantiomers of numerous drugs 
possessing point chirality have been shown to demonstrate drastically differing effects in the body.12 
Similarly, it has been found that the presence of the opposite atropisomer can result in off-target 
binding, and preorganizing (or locking) a freely rotating axis into the relevant configuration can 
increase target selectivity.10,13 Single-atropisomer drugs are available (Figure 3.3), though their 
locked configuration is rarely deliberate. For instance, drugs such as Viagra (sildenafil) and Imatinib, 
while not displaying obvious chirality, will bind to their receptors in an enantiospecific form.  
 
Meanwhile, configurationally stable scaffolds such as colchicine,14 gossypol15 and vancomycin16 
exist, but are frequently discovered as natural products and their high rotational barriers are as such 
not a design element. This is important because, as in the case of thalidomide, crucial differences in 
biology have been observed between separated atropisomers.10,13 (+)-Telenzepine, for example, is 
500 times more potent than (–)-Telenzepine,17 while the S atropisomer of colchicine is the only active 
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form.14 The design of single-atropisomer drugs would therefore represent a paradigm shift away 
from point chirality towards axial chirality for drug discovery. Two major hurdles have impeded 
these efforts thus far: 1) Exceptionally high rotational barriers (>28 kcal/mol) in vivo are needed to 
ensure long-term biological configurational stability,18 and 2) there exists a dearth of efficient 
synthetic methods to access such molecules. 
The following chapter will describe a solution to these challenges in the study of the 
rotational barriers and physical properties of troponoids. Owing to their ring size and increased 
bond angles, troponoids are predicted to 
have exceptionally high rotational 
barriers (Scheme 3.1). They also have 
exceptional bioactivity (see Chapters 1 
and 2). The combination of these 
properties makes troponoids ideal 
candidates for the development of single-
atropisomer drugs. However, they have 
historically represented a significant synthetic challenge; as such, there exists a scarcity of troponoid 
structure-function studies, with most current synthetic methods stifled by an inability to functionalize 
more than one position on the ring. Thus, the remainder of this chapter will discuss efforts to leverage 
ongoing synthetic studies in the Murelli lab towards the synthesis of configurationally stable troponoids. 
 
3.2. Discovery of α-Hydroxytropolone Atropisomerism 
3.2.1. 1H-NMR Profiles of a Troponoid and Benzenoid Thiazolidine 
As part of our ongoing medicinal chemistry studies, we synthesized thiazolidine 
α-hydroxytropone 3.4 via the oxidopyrylium cycloaddition/ring-opening route described in 
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Chapters 1 and 2 towards carboxylic acid 3.3 (Figure 3.4).19  Upon observing a remarkable degree 
of atropdiastereoselectivity by 1H-NMR, we became curious as to whether the analogous 
benzenoid would demonstrate similar properties at room temperature and thus carried out a similar 
amide coupling on benzoic acid 3.5. The resulting room temperature 1H-NMRs displayed very 
different profiles with the troponoid (Figure 3.4C, bottom, red) showing a clean set of AB quartets 
while the analogous thiazolidine signal on the benzenoid (Figure 3.4C, top, blue) presents as a set 
of singlets. 
 
3.2.2. Experimental Calculation of Thiazolidine Rotational Barriers 
 The reduced symmetry of the amide functionality in thiazolidines 3.4 and 3.6 enabled us 
to obtain kinetic parameters for Ar-CO atropisomerization via variable temperature 1H-NMR 
spectroscopy (Figure 3.5). Two moieties were investigated: the methylene in between the N and 
S (purple orb, Figure 3.4), and the methylene on the other side of the N (blue orb, Figure 3.4; see 
Supporting Information for details). The amide rotamers remained resolved over the course of 
these experiments, and we therefore were able to obtain rotational barrier measurements for each 
of the E/Z amide isomers. Benzenoid 3.6 was found to exist in rapid atropisomeric equilibrium at 
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25 °C, showing a single set of peaks for each E/Z amide rotamer with no atropdiastereotopic 
splitting. Therefore, the coalescence point of the benzenoid was met by cooling the sample down, 
while the troponoid required heating in order to observe coalescence. From this alone, a clear 
qualitative conclusion is evident: the benzenoid signals coalesce well before the troponoid signals 
(see Figure 3.5 and the Supporting Information). This pattern is evident across all signals 
belonging to both sets of molecules except for the most downfield methylene peak corresponding 
to the Z rotamer of the benzenoid. Initially, it was suspected that this rotamer may have a higher 
C-C rotational barrier; however, given that the other signals all coalesce, it can be concluded that 
the chemical shifts of the Z rotamers’ atropdiastereotopic protons are coincidentally equivalent.  
Since E/Z amide isomerization occurs at a significantly higher barrier than C-C 
isomerization, the ΔG‡ between 
the two atropisomeric forms (aS 
and aR) in solution were 
determined by lineshape 
simulation of VT-NMR spectra 
using iNMR modeling 
software.20 These lineshape 
simulations were based on the 
experimental spectra obtained 
for both compounds, 
specifically on the chemical 
shifts and coupling constants, 
and gave a rate constant (k) for each temperature. This data was converted into a barrier to rotation 
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at a given temperature by plotting 1/T vs ln(k/T) and performing an Eyring plot (see Supporting 
Information).21 This plot gives a straight line, the slope of which gives the enthalpy of rotation 
(ΔH‡) and the y-intercept of which gives the entropy of rotation (ΔS‡). Inserting these values into 
Gibbs’ equation for free energy gives the rotational energy (ΔG‡). In each case, the linear 
regression performed was obtained from a set of 5 data points with correlation coefficients between 
0.9855 and 0.9984, demonstrating a high degree of linearity for the data obtained.  
In the case of the benzenoid, C-N kinetic parameters were also analyzed by heating the 
sample in DMSO-d6 (Figure 3.5A). Troponoid C-N rotation remained too high in energy to be 
measurable within the temperature limitations of the NMR, but benzenoid C-N isomerization could 
be observed (ΔG‡ = 16.4 kcal/mol, see Supporting Information for details). This alone speaks to 
the levels of ancillary rigidity that can be provided by restricted C-C rotation in troponoids. All in 
all, the difference in rotational barriers between the 6- and 7-membered substrates is considerably 
large. To gain a better understanding of the physical basis of these differences, we turned to 
molecular modeling to assess the barriers of a small library of benzenoid and troponoid derivatives. 
 
3.3. Computational Modeling of Troponoids 
3.3.1. Preliminary Substrate Scope  
 This work was performed in collaboration with Dr. Anthony Metrano at Yale University 
and the approach used in these studies had been optimized for benzenoids22 and quinazolinones.23 
This work represents the first instance of a head-to-head comparison of benzenoid and troponoid 
side-chain rotational barriers via computational modeling, and one of the first extensive examples 
of troponoid rotational energy modeling entirely.24 Rotational barriers about the aryl/amide axis 
were performed using the OMEGA and GRACE supercomputer clusters provided by the Yale 
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University Faculty of Arts and Sciences High Performance Computing Center. All calculations 
were carried out using the Gaussian 09 suite.25,26  Ground state geometries were first optimized 
using density functional theory (DFT) at the B3LYP/6-31+G(d,p) level of theory.27 Harmonic 
vibrational frequencies were simultaneously calculated. The optimized structures were then used as 
foundations for a restricted torsional potential energy scan (PES) at the same level of theory. The 
scan was conducted by first defining the dihedral angle in question (CO-CAr) as the constrained 
coordinate and performing a scan of that angle through 360° in 10° increments using the same 
method and basis set.  
The resulting torsional profile was subsequently used as a starting point from which to 
narrow in on the single-point energies. The geometries of the scan maxima (transition states) were 
subjected to further optimization using B3LYP/6-31+G(d,p). The frozen single-point output 
geometries of these calculations, as well as the stationary ground state points on the torsional energy 
profile, were subjected to further optimization with no dihedral restrictions in place at the M06-2X/6-
311++G(2d,3p) level of theory and basis set.28 All calculations were performed at the gas phase. The 
output from these calculations were inspected, and in the case of the transition states, the imaginary 
frequency was verified as a vibration along the reaction coordinate of interest. The M06-2X total 
electronic energies were converted to Gibbs free energies and the barrier height ΔG‡ values were 
converted to kcal/mol from Hartrees using a conversion factor of 627.509 a.u. = 1 kcal/mol. The 
Arrhenius equation was then used to calculate rate constants for each barrier of the rotation (k1 and 
k2). These rate constants were then added to provide an observed rate constant, kobs. This value was 
used to calculate the observed barrier, ΔG‡(obs) using the following equation: 
 
Δ𝐺‡(𝑜𝑏𝑠) =  −𝑅𝑇 ∗ 𝑙𝑛
𝑘𝐵𝑇
ℎ𝑘𝑜𝑏𝑠
 (Eq. 3.1) 
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where R is the ideal gas constant [1.99 x 10-3 kcal/(molK)], T is the temperature in Kelvin, kB is the 
Boltzmann constant [1.38 x 10-23 (m2kg)/(s2K)], and h is Planck’s constant [6.63 x 10-34 (m2kg)/(s2)]. 
This approach was used to calculate rotational barriers for a series of methoxytropolones 
and their corresponding benzenoids. In order to minimize complicating factors such as 
tautomerization, we chose to focus on methoxytropolones as they are key intermediates in our 
synthetic route towards αHTs with only two possible tautomers. Given previous 2D-NMR29 and 
x-ray crystallographic30 evidence that the 7-methoxytropolone is the predominating tautomer, all 
troponoids were modeled in this form. These results are summarized in Table 3.1.  
 
During the course of these studies, a remarkable trend was observed: the troponoid substrates 
consistently displayed drastically increased rotational barriers when compared to their analogous 
benzenoids, with observed increases in half-life to racemization of up to 4 orders of magnitude. 
While we had anticipated that the decreased external bond angles of the troponoids would result in 
increased rotational barriers, the extent to which this effect was observed was particularly dramatic. 
Interestingly, the methyl ester (entry 4, Table 3.1) represents the sole exception to this trend - the 
transition state in the benzenoid isomerization pathway is orthogonal as opposed to co-planar, thus 
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losing the stabilizing effect of extended conjugation in the transition state. Nonetheless, in the 
interest of studying a biologically relevant system, we subsequently modeled thiazolidines 3.4/3.6.  
 
3.3.2. Computational Modeling of Benzenoid and Troponoid Thiazolidines 
The asymmetry of the amide moiety resulted in several complicating factors. The presence 
of non-degenerate E/Z amide rotamers gave rise to 4 unique ground states, each proceeding 
through one of three pathways to interconversion: rotation about the C-C axis, C-N axis, or a 
concerted mechanism (see Figure 3.6). Independent C-N bond rotation was computed to proceed 
through one of two degenerate transition states, depending on the direction of rotation: when the 
thiazolidine sulfur atom is proximal to the methyl group, the energy is increased and independent 
C-C rotation is not possible.  
Additionally, computations assessing the energy of C-C bond rotation lead to a concerted,31   
simultaneous rotation about the atropisomeric C-C axis and C-N axis.22b Compared to independent 
C-N rotation, which is a significantly higher energy process, this concerted C-N/C-C rotation 
represents the lowest energy pathway to amide isomerization (Figure 3.6). These computational 
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results imply that E/Z isomerization for a given enantiomer most likely involves first, a concerted 
rotation of the C-C and C-N axes, and second, an independent C-C rotation.  Regardless, the lowest 
energy atropisomeric racemization pathway was found to proceed via independent C-C rotation, 
as observed by 1H-NMR. The presence of DMSO in the troponoid experimental measurement 
likely accounts for the small differences between its calculated and experimental barriers. Even 
so, the benzenoid computed barriers were found to be in very good accord with the experimentally 
determined value. This data is summarized in Table 3.2. 
 
Ultimately, the differences in rotational barriers between the 6- and 7-membered substrates 
are notably large. We thus became curious if there was any way we could further exacerbate these 
differences, while simultaneously synthesizing high-rotational barrier troponoids. Given the vast 
literature precedence for employing halogenation on 6-membered homologs as a means of 
achieving configurational stability,22,23 we thought this seemed like feasible chemistry we could 
undertake on a troponoid. Prior to this synthetic work, we modeled brominated variants of the 






3.3.3. Modeling of Brominated 7-Methoxytroponoids and Benzenoids 
The same approach as described in Section 3.2.1 was utilized in the rotational barrier 
calculations on the brominated benzenoids and troponoids; the results are summarized in Table 
3.3. 
 
As expected, the brominated troponoids maintained dramatically higher barriers with 
respect to their respective benzenoids. This disparity is well exemplified by the piperidinyl-based 
scaffolds 3.18 and 3.23 (entry 2, Table 3.3), in which the half-life of racemization changes from 1.4 
hours to over 200 years. Even more astounding, however, is the difference between the brominated 
diisopropyl-based scaffolds 3.19 and 3.24 (entry 3), where the half-life of racemization increases 
from ~2 days to 7593 years!  
This intriguing disparity made us curious about the rotational energies of brominated but less 
sterically demanding substrates such as esters and ketones, which we subsequently modeled. As 
expected, they demonstrated low barriers to racemization even post-bromination, although the 
troponoids remained consistently higher. In all cases excluding R1 = OMe and R2 = R3 = H (entry 
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1, Table 3.1), the pathway of isomerization involves geared rotation about the CAr-CO and R1-CO 
axes in both the troponoids and the benzenoids.  
From this aggregate data, two key trends can be observed (Figure 3.7). Within the brominated 
molecules (R3 = Br), the troponoids were all computed at ~8 kcal/mol higher in energy than their 
analogous benzenoids. As well, the difference in rotational energies between non-brominated and 
brominated substrates is considerably higher for the tropolones than for the respective benzenoids (15.7 
vs 11.7 kcal/mol, where a bond rotation energy of >28 kcal/mol is necessary for configurational 
stability).18 As it appears that troponoids are more sensitive to structural changes than their respective 
benzenoid systems, our synthetic method towards αHTs could be utilized in the development of highly 










An eventual aim of this work is to develop single-atropisomer αHT derivatives for 
medicinal chemistry pursuits. The calculated troponoids are only a demethylation away from 
containing the active pharmacophore, and furthermore, contain an extremely useful handle for 
cross-coupling and further derivatization. As our standard demethylation conditions are run in 
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refluxing hydrobromic acid, and cross-coupling reactions will likely need to be run at elevated 
temperatures, we computed rotational barriers for 3.8 and 3.18 at 125 °C (entries 6 and 7, Table 
3.3). The barriers increase slightly at elevated temperatures due to increases in the entropic 
component of ΔG‡. However, the half-life does decrease substantially. Thus, the temperatures of 
future functionalization reactions will need to be kept in mind.  
While these results are highly promising, the calculations are not without limitations. The 
approach employed was developed for benzenoids22a and quinazolinones,23a and troponoid 
characteristics such as tautomerization,32 puckering,33 and electronic properties such as decreased 
aromaticity34 can all influence the actual rotational barrier. Furthermore, even small changes in high-
value free energy calculations can produce large rate effects since rate increases exponentially with ΔG. 
With this in mind, we modeled the tautomeric forms of 3.8 and 3.18 (3.8b and 3.18b; entries 8 and 9, 
Table 3.3) and found that while the two sets of tautomers have nearly identical respective ground state 
energies, the second tautomer enantiomerizes through a considerably higher energy pathway (i.e. 3.18 
versus 3.18b, entries 2 versus 9, Table 3.3). This may result from repulsion between the carbonyl oxygen 
(which has anionic character resulting from troponoid aromaticity, requiring a formal positive charge on 
the carbonyl carbon) and the adjacent bromide. Regardless, we reasoned that racemization occurs 
predominantly via the first tautomer, which was the same tautomeric form assessed in all of the 
computations described above. We then set about confirming these higher rotational barriers 
experimentally. 
 
3.4. Synthesis of Bromotropolones: Experimental Confirmation of Higher Barrier Molecules 
 Bromotroponoids had previously shown utility in some of our own medicinal chemistry 
pursuits.35 In several cases, adding a halogen has increased the bioactivity over the parent scaffold, 
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and the added electron density provided by the halogens can yield higher quality x-ray crystal 
structures by increasing the atomic scattering factor.36 In addition, there are many examples in the 
literature of halogens increasing barriers to rotation about an adjacent axis22,23,37 with biomedical 
benefits.38 For example, this strategy has been leveraged by the Gustafson lab in the synthesis of 
a series of chlorinated kinase inhibitors, where it was found that the different atropisomers had 
drastically different biological activity (Scheme 3.2).39 Given these factors, we set out to develop 
a synthetic route to halotropolones. Early synthetic efforts utilizing bromomethylpropiolate 3.30 




As this ester was not computationally predicted to be configurationally stable, we turned 
our attention to piperidinyl amide 3.18. This molecule was first synthesized via an oxidopyrylium 
cycloaddition using bromoalkyne 3.34b to access bicyclic intermediate 3.35b, which was 
subsequently converted to methoxytropolone 3.18 via a triflic acid-mediated ring opening. 
Unfortunately, attempts to demethylate the analogous iodo-based methyl ester methoxytropolone 
lead to a mixture of products, while the strong lachrymator properties of bromopropiolates posed 
technical challenges. To overcome these difficulties, we developed a regioselective electrophilic 




3.5.  Experimental Validation of Bromotropolone Rotational Barriers 
 In order to obtain experimental rotational barrier measurements of 3.18, we attempted to 
separate the enantiomers via HPLC. Unfortunately, while we were able to obtain analytical 
chromatographic conditions to resolve the atropisomers of 3.18, attempts to separate the 
enantiomers via preparatory scale HPLC proved problematic owing to the low separation factor of 
the peaks. 
Instead, we sought to obtain enantioenriched material and monitor thermal racemization, 
and so we turned our attention to a dynamic, kinetic peptide-catalyzed atropselective halogenation 
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strategy developed by the Miller group (i.e. 3.36a → 3.36b, Scheme 3.4A).22a This approach, first 
published in Science in 2010,41 exploits the differences in rotational barriers around a chiral axis 
before and after bromination and has been applied to biaryls,41,42 quinazolinones,23a and 
benzamides.22a To the best of our knowledge, the only atropselective halogenation on a non-phenolic 
system was reported in 2016 towards the groundbreaking asymmetric total synthesis of natural 
product marinopyrrole A.43 Unfortunately, this route suffered from low selectivity (11% ee); as such, 
Miller’s work represents the current state-of-the-art in atropselective halogenation. 
The selectivity of Miller’s work, delivered by the peptide catalyst, is provided through a 
hydrogen bond network involving an H-bond donor and acceptor flanking the bromination site on 
the axially chiral substrate (see Scheme 3.4). As these features are shared by our troponoid scaffolds, 
we became intrigued by the possibility of using this method to halogenate troponoids. Thus, we 
initiated a collaboration with the Miller group to develop the first published method for catalytic, 
atropselective troponoid synthesis. After some optimization (see Chapter 4 for details), we were able 
to identify conditions that provided methoxytropolone 3.18 in 75:25 er via catalyst 3.38. While 
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efforts remain underway to increase selectivity, this method proved sufficient for obtaining optically 
enriched material for measuring experimental rotational energy barriers.  
 
3.5.1. Determination of Rotational Barrier via Thermal Erosion of Enantiopurity 
 Racemization studies were performed on 3.18 to obtain its barrier to rotation (Figure 
3.8).44 A solution (5.6 mM) of 3.18 (50% ee) in triethylene glycol dimethyl ether (triglyme) was 
heated in an oil bath at 145 °C. The enantiomeric ratio was measured by reversed phase chiral 
HPLC at time points spanning 2 to 60 minutes. Plots of ee versus time, and of ln(1/ee) versus time 
resulted in the respective graphs shown below. Using the slope of these lines and the Eyring 
equation, the free activation energy was determined and it was found that 3.18 has a barrier to 
rotation of 30.1 kcal/mol at 145 °C. Owing presumably to hydrogen bonding effects with the glyme 
solvent, the experimental value is slightly lower than that computed at 145 °C (ΔG‡ = 32.7 
kcal/mol), though certainly within the range of experimental error. Thus, experimental data clearly 
indicates that 3.18 has exceptionally high configurational stability and helps further illustrate the 






3.6.  Resolution of a Single-Atropisomer α-Hydroxytropolone 
  Given the generally high rotational barriers of troponoids, we became interested in 
leveraging this quality towards developing molecules with biomedical utility. Recently, there has 
been a growing appreciation for atropisomerism in drug development and for designing 
atropisomerism in order to increase target specificity. Given the wealth of biological targets known 
to be accessible to αHTs, we decided to resolve optically pure αHTs for future biological testing. 
Simple demethylation using our standard conditions (refluxing HBr/AcOH) was effective for the 
piperidinyl substrate. The enantiomers were successfully resolved via preparatory CSP-HPLC to 
a high degree of optical purity and their relative stereochemistry was determined (MPLC 
Chiralflash IC: Ent-1: (+)-3.39, >99:1 er; Ent-2: (-)-3.39, 97:3 er), setting the stage for future 
biological testing. Additionally, (-)-3.39 was found to be stable at physiological conditions (in a 
4.4 mM solution of PBS buffer, pH 7.4, at 37 °C) for 24 hours with no loss of enantioenrichment 
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observed over this timeframe, further demonstrating the potential value of rotationally restricted 





3.7. Optical Assignment of Bromotroponoid Enantiomers 
 With optical rotation measurements of enantiopure [(+)-3.39] and enantioenriched 
[(-)-3.39] in hand, we set about determining the relative stereochemistry of 3.18 in order to 
determine the preference of peptide 3.38 for formation of (+) or (-) product. To this end, we 
subjected enantioenriched 3.18 to our demethylation conditions.45 With a computed t1/2 of ~7 hours 
at the demethylation temperature of 125 °C, we anticipated seeing erosion of enantioenrichment – 
though not full racemization – within 30 minutes. Thus, we subjected 3.18 to these conditions, and 
gratifyingly found some retention of enantioenrichment (50% ee → 28% ee). From the HPLC trace 
of enantioenriched 3.39 as well as analogy to a previously reported atropselective halogenation 
(3.36a → 3.36b vs. 3.8 → 3.18, Scheme 3.12),22a we were able to infer that peptide 3.38 favors 
formation of the second-eluting (-) enantiomer (Figure 3.9). Depending on the relative 
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bioactivities of (+)- and (-)-3.39, future atropselective synthetic efforts towards single-enantiomer 
troponoids may benefit from this knowledge. 
 
 
3.8.  Conclusions   
Atropisomerism has an established and valuable role in a variety of scientific pursuits and 
troponoids possess unique structural properties resulting in increased rotational barriers that are of 
high interest in related studies. As such, computational and experimental rotational barriers 
measured on tropamides revealed that troponoid-based chiral axes have substantially higher 
rotational barrier measurements when compared to analogous benzenoid systems. Critical to the 
achievement of this discovery was the computational modeling of a library of axially chiral aryl 
systems, as well as the development of a catalytic atropselective halogenation on a novel troponoid 
substrate. Optimization of this reaction will allow us to aid in an emerging paradigm shift towards 
studying designed and restricted axial chirality in drug development. 
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3.10. Supplementary Experimental Details 
 Computational studies on the methoxytropolones and analogous benzenoids were 
performed in collaboration with Dr. Anthony Metrano. Elizabeth Stone and Dr. Golo Storch 
performed the computational studies on the thiazolidines. All of these computational details can 
be found in the Supporting Information for this manuscript.S1 
 
3.10.1. General Information 
All starting materials and reagents were purchased from commercially available sources 
and used without further purification, with exception of CH2Cl2, which was purified on a solvent 
purification system prior to the reaction. All reactions were performed in oven- or flame-dried 
glassware. 1H-NMR shifts are measured using the solvent residual peak as the internal standard 
(CHCl3δ7.26, MeOH δ 3.31, CH2Cl2 δ 5.32, DMSO δ 2.50), and reported as follows: chemical 
shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet of doublet, 
q = quartet, m = multiplet, dd = doublet of doublets, ddd = doublet of doublet of doublets, dt = 
doublet of triplets, dq = doublet of quartet, ABq = AB quartet), coupling constant (Hz), and 
integration. 13C NMR shifts are measured using the solvent residual peak as the internal standard 
(CHCl3 δ77.2, MeOH δ 49.0, DMSO δ 39.5), and reported as chemical shifts. Infrared (IR) 
spectral bands are characterized as broad (br), strong (s), medium (m), and weak (w). Microwave 
reactions were performed via the Biotage Initiator 2.5. Analytical thin-layer chromatography 
(TLC) was performed using Silica Gel 60 Å F254 pre-coated plates (0.25 mm thickness). TLC Rf 
values are reported, with visualization accomplished by irradiation with a UV lamp or 
appropriate TLC stain. Purification via normal phase column chromatography was performed on 




acetate and hexanes. Reversed phase chromatography was performed on the Biotage Isolera 
Prime with Biotage SNAP C18 12 g cartridges, in a solvent system of water and acetonitrile with 
a 0.05% trifluoroacetic acid additive. Column gradients are measured in terms of column 
volumes (CV). Mass spectra were recorded on a spectrometer by the electrospray ionization 
(ESI) technique with a time-of-flight (TOF) mass analyzer. Commercially available 
dibromodimethylhydantoin (DBDMH) and N-bromosuccinimide (NBS) were purified by 
recrystallization from hot water. Optical rotations were recorded on a Perkin-Elmer Polarimeter 
341 at the sodium D line (1.0 dm path length). Reverse-phase HPLC analysis was conducted 
with an Agilent 1100 series instrument equipped with a diode array detector (λ = 265 nm) and 
columns (chiral supports) from Daicel Chemical Industries (Chiralpak IA and Chiralpak IC) at 
ambient temperature. Reverse phase preparatory HPLC separation was performed on the Biotage 
Isolera Prime with a 30 x 100 mm (20 µm particle size) Chiralflash IC column. 
 
3.10.2. Synthesis and characterization of 3-bromo-1-(piperidin-1-yl)prop-2-yn-1-one (3.34b) 
 
Procedure: To a solution of 1-(piperidin-1-yl)prop-2-yn-1-one 3.34aS2 (563.9 mg, 4.11 mmol) 
in acetone (8.22 mL) was added N-bromosuccinimide (804.6 mg, 4.52 
mmol). After stirring for 5 minutes, silver nitrate (69.63 mg, 0.411 mmol) 
was added slowly ambient temperature. The reaction was allowed to stir for 
1.5 hours in the dark before being quenched by 10 mL of water. The reaction mixture was added 




aqueous layer was extracted with CH2Cl2 (3 x 10 mL). Combined organics were extracted with 
20 mL of water, 20 mL of saturated sodium bicarbonate solution, and 20 mL of aqueous sodium 
chloride. Combined organics were dried over Na2SO4, filtered, and concentrated under reduced 
pressure to yield 3.34b as a light yellow solid (774.6 mg, 87% yield). Melting point (mp) = 
54-56 °C. Rf= 0.35 in 25% EtOAc in hexanes. IR (thin film, KBr) 3443 (br), 2941 (w), 2857 
(w), 2098 (m), 1628 (s), 1441 (m), 1268 (w), 1223 (w), 1142 (w), 1014 (w) cm-1. 1H NMR (400 
MHz, CDCl3) δ 3.76 – 3.62 (t, 2H), 3.62 – 3.48 (t, 2H), 1.73 – 1.59 (m, 4H), 1.59 – 1.49 (m, 
2H). 13C NMR (100 MHz, CDCl3) δ 151.7 (s), 73.7 (s), 55.3 (s), 48.3 (s), 42.7 (s), 26.6 (s), 25.5 
(s), 24.6 (s). HRMS (ESI+) m/z calc’d for C8H11BrNO
+: 216.0019. Found: 216.0025.  
 
3.10.3. Synthesis and characterization of 8-oxabicyclo[3.2.1]octene (3.35a) 
 
 3-methoxy-5-methyl-6-(piperidine-1-carbonyl)-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one 
(3.35a). To a solution of dimer 3.28b (325 mg, 1.16 mmol) in DCM (4.63 mL) 
was added 1-(piperidin-1-yl)prop-2-yn-1-one 3.34a (954.3 mg, 6.96 mmol). 
After heating in an oil bath at 100 °C for 90 min, the reaction mixture was 
purified by chromatography (Biotage Isolera Prime, 25 g silica gel column 
capped with triethylamine, solvent gradient: 2% EtOAc in hexanes (3 CV); 2-10% EtOAc in 
hexanes (5 CV); 15-25% EtOAc in hexanes (15 CV); 25-35% EtOAc in hexanes (8 CV); 35-




122-124 °C (417.9 mg, 65% yield). Rf= 0.32 in 25% EtOAc in hexanes. IR (thin film, KBr) 
2937 (s), 2858 (s), 1708 (s), 1605 (s), 1443 (s), 1375 (w), 1347 (w), 1286 (m), 1179 (m), 1130 
(m), 1078 (m), 988 (m), 863 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.26 (d, J = 2.4 Hz, 1H), 
6.23 (s, 1H), 5.07 (d, J = 2.4 Hz, 1H), 3.68 – 3.59 (m, 2H), 3.57 (s, 3H), 3.54 – 3.44 (m, 2H), 
1.74 – 1.64 (m, 2H), 1.61 (s, 3H), 1.59 – 1.49 (m, 4H). 13C NMR (100 MHz, CDCl3) δ 188.6, 
163.6, 150.6, 144.9, 127.5, 121.4, 87.2, 86.7, 54.6, 47.7, 42.6, 26.8, 25.6, 24.5, 20.5. HRMS 
(ESI+) m/z calc’d for C15H20NO4
+: 278.1387. Found: 278.1390. 
 
3.10.4. Synthesis and Characterization of Troponoids via Triflic Acid 
 
 2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1-carbonyl)cyclohepta-2,4,6-trien-1-one 
(3.8). To a solution of 8-oxabicyclo[3.2.1]octane intermediate 3.35a (100.4 mg, 0.362 mmol) in 
dried, deacidified DCM (3.60 mL) was added triflic acid (128.1 μL, 
1.5 mmol). The reaction was allowed to stir for 35 minutes at rt before 
quenching with pH 7 phosphate buffer and extracting with CH2Cl2.  
Combined organics were dried over Na2SO4, filtered, and 
concentrated under reduced pressure to yield 3.8 as a pale green/brown solid that melts at 166-
169 °C (97.3 mg, 97% yield). IR (thin film, KBr) 3447 (br), 2938 (m), 2856 (m), 1735 (w), 
1620 (s), 1560 (m), 1446 (m), 1325 (w), 1257 (s), 1136 (w), 1152 (w), 1026 (w), 996 (w). 1H 




3.10 (m, 2H), 2.41 (s, 3H), 1.67 (d, J = 4.7 Hz, 4H), 1.61 – 1.37 (m, 2H). 13C NMR (100 MHz, 
CDCl3) δ 170.5, 168.7, 159.6, 158.6, 136.7, 132.9, 121.6, 115.9, 56.5, 47.7, 42.5, 26.4, 25.5, 
24.4, 24.3. HRMS (ESI+) m/z calc’d for C15H20NO4
+: 278.1387. Found: 278.1380. 
 
 3-bromo-2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1-carbonyl)cyclohepta-2,4,6-trien-
1-one (3.18). To a solution of dimer 3.28b (45.8 mg, 0.163 mmol) in DCM (577 μL) was added 
3-bromo-1-(piperidin-1-yl)prop-2-yn-1-one (3.34b) (312.1 mg, 1.44 
mmol). After microwave irradiation at 100 °C for 35 min, the reaction 
mixture was purified by chromatography (Biotage Isolera Prime, 10 g 
silica gel column, solvent gradient: 5% EtOAc in hexanes (3 CV); 5-
15% EtOAc in hexanes (15 CV); 15-25% EtOAc in hexanes (15 CV); 25-35% EtOAc in hexanes 
(8 CV); 35-50% (5 CV)). Product fractions were concentrated to yield 3.35b as a semi-pure 
product that was used without further purification. To a solution of 8-oxabicyclo[3.2.1]octane 
intermediate 3.35b (10.9 mg, 0.031 mmol) in dried, deacidified DCM (305 μL) was added triflic 
acid (10.8 μL, 0.122 mmol). The reaction was allowed to stir for 30 minutes at rt before 
quenching with pH 7 phosphate buffer and extracting with CH2Cl2.  Combined organics were 
dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 3.8 as a pale 
yellow/brown waxy solid (6.3 mg, 50% yield over two steps). IR (thin film, KBr) 3424 (br), 
2936 (w), 2854 (w), 1632 (w), 1571 (m), 1445 (w), 1352 (m), 1265 (m), 1247 (w), 1169 (w), 
1136 (w), 1077 (w), 787 (w). 1H NMR (400 MHz, CDCl3) δ 7.02 (s, 1H), 4.01 (s, 3H), 3.90 – 
3.56 (m, 2H), 3.32 – 3.10 (m, 2H), 2.48 (s, 3H), 1.86 – 1.57 (m, 4H), 1.57 – 1.41 (m, 2H). 13C 




42.4, 26.1, 26.0, 25.2, 24.5. HRMS (ESI+) m/z calc’d for C15H19BrNO4
+: 356.0492. Found: 
356.0502. 
 
3.10.5. Synthesis and Characterization of Troponoids via Electrophilic Aromatic Substitution 
 
3-bromo-2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1-carbonyl)cyclohepta-2,4,6-trien-1-
one (3.18). Procedure A: To a solution of 2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1-
carbonyl)cyclohepta-2,4,6-trien-1-one 3.8 (10.8 mg, 0.039 mmol) in 
CDCl3 (1.30 mL) was added dibromodimethylhydantoiin (DBDMH) 
(14.25 mg, 0.05 mmol), followed by triethylamine (5.4 μL, 0.039 
mmol). The reaction was allowed to stir for 2 hours at rt before 
quenching with pH 3 phosphate buffer and extracting with CH2Cl2.  Combined organics were 
dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 3.18 as a pale 
yellow/brown waxy solid (5.6 mg, 88% yield) with 1H-NMR data consistent with previously 







Procedure B: N-Bromosuccinimide (NBS, 1.1 equiv.) was added to a 0.02 M solution of 
tropamide 3.8 (17.3 mg, 0.062 mmol, 1 equiv) and catalyst 3.38 (3.5 
mg, 0.006 mmol, 0.1 equiv) in CDCl3 (3.12 mL) at 0 ºC. The reaction 
was allowed to stir for 72 hours. The reaction was then diluted with 4 
mL of DCM, transferred to a separatory funnel, and quenched with an 
equivalent volume of a pH 3 phosphate buffer (made by diluting 1.7 mL of 2.0 M aqueous 
sulfuric acid with 12 mL of 1.0 M pH 7 phosphate buffer), and extracted 3x. The combined 
organics were dried over sodium sulfate, filtered, and concentrated under reduced pressure. 
Reversed phase chromatography of the crude residue with water/acetonitrile was accomplished 
on a Biotage Isolera Prime (SNAP 12g C18 silica gel column, solvent gradient: 10% acetonitrile 
in water (3 CV); 10-23% (8 CV), 23-35% (8 CV), 35-100% (6 CV); acetonitrile and water each 
contained 0.05% TFA). Product fractions were combined, extracted with excess DCM (3x, Σ = 
60 mL), filtered through Na2SO4 and concentrated at 30 °C in vacuo, yielding 3.18 as a waxy 
brown/yellow solid (11.2 mg, 50% yield) with 1H-NMR data consistent with previously reported 
data. See Section 3.10.4 for characterization data. HPLC 75:25 er (Chiralpak IA, 1.5 mL/min, 








3.10.6. Synthesis and Chiral Resolution of αHT 3.39 
 
3-bromo-2,7-dihydroxy-5-methyl-4-(piperidine-1-carbonyl)cyclohepta-2,4,6-trien-1-one 
(3.39).  Procedure: To methoxytropolone 3.18 (20.3 mg, 0.057 mmol) was added 892 μL of 33% 
HBr/AcOH. The reaction was heated in a sealed tube to reflux at 120 °C for 
30 minutes before being quenched to pH 4 with pH 7 phosphate buffer. The 
organic layer was isolated and the aqueous later was extracted with CH2Cl2 (5 
x 10 mL). Combined organics were dried over Na2SO4, filtered, and 
concentrated under reduced pressure to yield 3.39 as a waxy brown solid (14.6 mg, 75%). HPLC 




11.0 min, RT(Ent-2) = 13.7 min; IR (thin film, KBr) 3420 (br), 2936 (m), 2856 (m), 1633 (s), 
1542 (m), 1445 (s), 1270 (w), 1230 (w), 1137 (w), 1067 (s), 810 (w), 735 (w). 1H NMR (200 
MHz, CDCl3) δ 7.43 (s, 1H), 3.92 – 3.54 (m, 2H), 3.23 – 3.05 (m, 2H), 2.47 (s, 3H), 1.83 – 1.56 
(m, 4H), 1.56 – 1.38 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 167.2, 165.3, 157.0, 156.3, 139.8, 
134.9, 123.8, 119.6, 47.2, 42.3, 25.9, 25.7, 25.2, 24.5. HRMS (ESI+) m/z calc’d for C14H17NO4
+: 
342.0335. Found: 342.0390. 
 
Preparatory Chromatography. 10.0 mg of 3.39 were loaded onto a Chiralflash IC column (100 
mm, i.d. 30 mm, particle size 20 μm) fitted with adaptors for use with an MPLC Biotage Isolera 
Prime. Conditions: water/acetonitrile/formic acid (70:30:0.1, v/v/v), 12 mL/min, direct load in 
water/acetonitrile (30:70, v/v). Fractions containing product for both enantiomers were combined 
separately, extracted with excess DCM (3x, Σ = 300 mL), filtered through Na2SO4 and 
concentrated at 30 °C in vacuo, yielding a total of 2.3 mg of 3.39-(Ent-1) and 4.5 mg 3.39-(Ent-






Assessment of chemical purity. Racemic material (red trace, bottom) and isolated enantiomers 
(Ent-1 = green trace, middle; Ent-2 = purple trace, top) were compared via UPLC-MS. 
Calculated m/z for C14H17NO4




Assessment of enantiopurity. Each sample was assessed via the reversed phase CSP-HPLC 
conditions previously described. 3.39-(Ent-1): >99:1 er. 3.39-(Ent-2): 97:3 er. 
 







3.39-(Ent-1): >99:1 e.r. 
 
 








2,7-dihydroxy-4-methyl-5-(thiazolidine-3-carbonyl)cyclohepta-2,4,6-trien-1-one (3.4).  
Procedure: To a solution of carboxylic acid3 3.3 (25.0 mg, 0.127 mmol) in THF (3.18 mL) was 




hexafluorophosphate (PyBOP) (73 mg, 0.140 mmol). The mixture was 
allowed to stir for 15 min in the dark at rt under an atmosphere of argon gas. 
Thiazolidine (11.1 μL, 0.140 mmol) was then added to the solution. The 
reaction was subjected to microwave irradiation at 85 °C for 10 min, 
concentrated in vacuo, and dissolved in 800 uL of DMSO for purification via 
reverse phase chromatography (Biotage Isolera Prime, SNAP 12g C18 silica gel column, solvent 
gradient: 0% acetonitrile in water (3 CV); 0-15% (15 CV); 15-25% (20 CV); 25-50% (8 CV); 
50-100% (10 CV); acetonitrile and water each contained 0.05% TFA). Product fractions were 
concentrated in vacuo to remove acetonitrile, and the remaining aqueous solution was extracted 
with DCM (3 x 15 mL). The combined organics were dried over sodium sulfate, filtered, and 
concentrated in vacuo to yield 3.4 as a yellow oil (11.8 mg, 35 % yield). IR (thin film, KBr) 
3442 (br), 2075 (w), 1637 (m), 1545 (w), 1488 (w), 1302 (w), 1145 (w), 1056 (w), 1033 (w), 781 
(w), 537 (w) cm-1. 1H NMR (400 MHz, MeOD) δ 7.45 (s, 2H), 7.23 (d, J = 2.0 Hz, 2H), 4.71 
(ABq, 2H, JAB = 10.3 Hz), 4.29 (ABq, 2H, JAB =  9.5 Hz), 4.02 – 3.84 (m, 2H), 3.63 – 3.43 (m, 
2H), 3.23 – 3.12 (m, 2H), 3.11 – 3.00 (m, 2H), 2.36 (d, J = 1.4 Hz, 6H).13C NMR (100 MHz, 
DMSO) δ 168.3, 168.3, 167.7, 167.5, 159.3, 159.2, 158.2, 158.2, 135.8, 135.5, 134.7, 134.4, 
123.5, 123.4, 117.6, 117.6, 50.1, 49.3, 47.3, 47.0, 30.34, 29.3, 22.9, 22.8. For 2D NMR 
experiments, see Section 3.10.10. HRMS (ESI+) m/z calc’d for C12H14NO4S
+: 268.0638. Found: 
268.0639. 
 
(5-hydroxy-2-methylphenyl)(thiazolidin-3-yl)methanone (3.6).  
Procedure: To a solution of carboxylic acid 3.5 (19.3 mg, 0.127 mmol) in THF (3.18 mL) was 




hexafluorophosphate (PyBOP) (73 mg, 0.140 mmol). The mixture was 
allowed to stir for 15 min at rt under an atmosphere of argon gas. Thiazolidine 
(11.1 μL, 0.140 mmol) was then added to the solution. After microwave 
irradiation at 85 °C for 10 min, the reaction mixture was purified by chromatography (Biotage 
Isolera Prime, 10 g silica gel column, solvent gradient: 5% EtOAc in hexanes (3 CV); 5-25% 
EtOAc in hexanes (12 CV); 25-30% EtOAc in hexanes (5 CV); 30-50% EtOAc in hexanes (10 
CV); 50-100% (20 CV)). Product fractions were concentrated to yield 3.6 as a white solid (16.2 
mg, 57% yield). Rf= 0.22 in 50% EtOAc in hexanes Melting point (mp) = 139-141 °C. IR (thin 
film, KBr) 3423 (br), 1608 (s), 1450 (s), 1336 (w), 1291 (m), 1261 (w), 1236 (m), 1095 (w), 822 
(w), 713 (w) cm-1. 1H NMR (400 MHz, CDCl3) 
1H NMR (400 MHz, CDCl3) ä 7.51 – 7.28 (bs, 
2H), 7.01 (dd, J = 8.3, 3.9 Hz, 2H), 6.76 – 6.68 (m, 2H), 6.61 (dd, J = 8.0, 2.3 Hz, 2H), 4.75 (s, 
2H), 4.20 (s, 2H), 3.99 (t, J = 6.5 Hz, 2H), 3.49 (t, J = 6.2 Hz, 2H), 3.11 (t, J = 6.5 Hz, 2H), 2.95 
(t, J = 6.2 Hz, 2H), 2.19 (d, J = 4.3 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 170.4, 170.2, 
154.7, 136.9, 136.6, 132.0, 131.9, 125.1, 124.7, 117.4, 117.4, 113.0, 112.9, 51.2, 50.4, 47.9, 47.6, 
30.9, 30.3, 18.1. For 2D NMR experiments, see Section 3.10.10.. HRMS (ESI+) m/z calc’d for 
C11H14NO2S
+: 224.0740. Found: 224.0778. 
 
3.10.8. Determination of Kinetic Parameters via Dynamic NMR Studies  
Lineshape simulation of the spectra was performed using the iNMR software (Version 6), 
which gave a rate constant (k) at a range of temperatures. These were converted into rotational 











The plot of ln(k/T) vs 1/T gives a straight line fitting the form y=mx+b. The slope (m) gives the 
enthalpy of rotation (ΔH‡): 
 Eq. S3.2 
 




Inserting these values into Gibbs’ equation for free energy (ΔG‡ = ΔH‡ – TΔS‡) gives an 
estimation of ΔG‡298K. (kB – Boltzmann constant, h – Planck’s constant, R – universal gas 

















A) Determination of C-C Barriers 
 
 For troponoid 3.4, lineshape fitting was performed on peaks AZ, BZ, CZ, AE, and BE. Due 
to its complex splitting pattern, accurate simulation of troponoid signal CE proved problematic. 
The reported kinetic parameters (Figure S3.1) represent averages of the values obtained for these 
signals. Fitting 1H-NMR data at temperatures above 353 K was impractical due the amide 
rotamer signals beginning to coalescence. In the case of benzenoid 3.6, lineshape fitting was 
performed on AE, BZ, BE, and CE. Simulation of peak CZ proved similarly challenging, and 
resolution of peak AZ was not observed. While it was initially suspected that this effect may be 
indicative of rotamer Z possessing a higher energy C-C barrier, given that the other Z signals all 
coalesce, it can be concluded that the chemical shifts of the Z rotamer’s atropdiastereotopic 




Troponoid 3.4: Peak AZ 
 
T (K) 1/T (K-1) k (s-1) ln(k/T) 
298 0.003354 4.5 -4.194 
323 0.003095 21 -2.734 
333 0.003002 45 -2.002 
343 0.002914 89 -1.349 
353 0.002832 167.3 -0.747 
 
Table S3.1. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic 
parameters from peak AZ of troponoid 3.4. 
 
Troponoid 3.4: Peak AE  
 
T (K) 1/T (K-1) k (s-1) ln(k/T) 
298 0.003354 2.37 -4.835 
323 0.003095 16.37 -2.982 
333 0.003002 35.37 -2.243 
343 0.002914 72.64 -1.553 
353 0.002832 159.19 -0.797 
 
Table S3.2. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic 
parameters from peak AE of troponoid 3.4. 
 
Troponoid 3.4: Peak BE 
 
T (K) 1/T (K-1) k (s-1) ln(k/T) 
298 0.003354 5.5 -3.993 
323 0.003095 17.5 -2.916 
333 0.003002 36.5 -2.211 
343 0.002914 66 -1.649 
353 0.002832 106.1 -1.202 
 
Table S3.3. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic 





Troponoid 3.4: Peak BZ 
 
T (K) 1/T (K-1) k (s-1) ln(k/T) 
298 0.003354 5 -4.088 
323 0.003095 25.5 -2.539 
333 0.003002 45 -2.002 
343 0.002914 89 -1.350 
353 0.002832 152.73 -0.838 
 
Table S3.4. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic 
parameters from peak BZ of troponoid 3.4. 
 
Troponoid 3.4: Peak CZ 
 
T (K) 1/T (K-1) k (s-1) ln(k/T) 
298 0.003354 5 -4.088 
323 0.003095 26 -2.520 
333 0.003002 63.5 -1.658 
343 0.002914 92 -1.316 
353 0.002832 n/a n/a 
 
Table S3.5. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic 
parameters from peak CZ of troponoid 3.4. 
 
Benzenoid 3.6: Peak AE 
 
T (K) 1/T (K-1) k (s-1) ln(k/T) 
213 0.004692 5 -3.752 
223 0.004481 19.7 -2.427 
233 0.004289 62.7 -1.313 
243 0.004113 144.08 -0.523 
258 0.003874 421.5 0.490 
 
Table S3.6. Rate constants k for isomerization at given temperatures T, with Eyring plot used to 





Benzenoid 3.6: Peak BE 
 
T (K) 1/T (K-1) k (s-1) ln(k/T) 
213 0.004692 13.5 -2.759 
223 0.004481 34 -1.881 
233 0.004289 87.5 -0.980 
243 0.004113 197.34 -0.209 
258 0.003874 476.2 0.612 
 
Table S3.7. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic 
parameters from peak BE of benzenoid 3.6. 
 
Benzenoid 3.6: Peak BZ 
 
T (K) 1/T (K-1) k (s-1) ln(k/T) 
213 0.004692 5 -3.752 
223 0.004481 19.5 -2.437 
233 0.004289 54.5 -1.454 
243 0.004113 69 -1.260 
258 0.003874 600 0.843 
 
Table S3.8. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic 
parameters from peak BZ of benzenoid 3.6. 
 
Benzenoid 3.6: Peak CE 
 
T (K) 1/T (K-1) k (s-1) ln(k/T) 
213 0.004692 12 -2.877 
223 0.004481 29 -2.051 
233 0.004289 61 -1.341 
243 0.004113 162.22 -0.405 
258 0.003874 617.14 0.872 
 
Table S3.9. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic 





B) Determination of Benzenoid C-N Barrier 
For benzenoid 3.6, lineshape fitting to determine the C-N amide isomerization barrier was 
performed on peaks AE and AZ. Since there is a slightly higher population of the Z rotamer as 
visible by 1H-NMR (integration of AE:AZ = 1.0:1.1), separate analyses were carried out for each 
isomer (Figure S3.2). As this effect is minor, the reported rotational barrier (see main text) 
represents an average of these two values. 
 
 
 Analysis of the ‘A’ peaks gave rate constants k at temperatures spanning 298-373 K 
(Tables S3.10-S3.11). Using the method described above, these rate constants were used to 










Benzenoid 3.6: Peak AZ (representing Z  E isomerization) 
 
T (K) 1/T (K-1) k (s-1) ln(k/T) 
298 0.003354 6.50 -3.826 
303 0.003299 7.25 -3.733 
313 0.003193 18.25 -2.842 
323 0.003095 36.75 -2.174 
333 0.003002 81.75 -1.405 
343 0.002914 157.70 -0.777 
353 0.002832 307.54 -0.138 
363 0.002754 627.12 0.546 
373 0.002680 1027.00 1.012 
 
Table S3.10. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic 
parameters from peak AZ of benzenoid 3.6.  
 
Benzenoid 3.6: Peak AE (representing E  Z isomerization) 
 
T (K) 1/T (K-1) k (s-1) ln(k/T) 
298 0.003354 7.50 -3.683 
303 0.003299 8.25 -3.604 
313 0.003193 23.75 -2.580 
323 0.003095 44.25 -1.988 
333 0.003002 87.75 -1.334 
343 0.002914 169.17 -0.707 
353 0.002832 336.57 -0.048 
363 0.002754 627.12 0.546 
373 0.002680 1027.00 1.012 
 
Table S3.11. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic 






3.10.9. Experimental Barrier Determination of 3.18 via Thermal Racemization 
To an oven-dried 1 dram vial equipped with a stir bar was added a solution (5.6 mM) of 
3.18 (5.0 mg, 50% ee) in triethylene glycol dimethyl ether (triglyme, 2 mL). The vial was sealed 
with a puncturable septa-lined cap and heated in an oil bath (equipped with a temperature probe 
and a thermometer to confirm temperature) at 145 °C. The enantiomeric ratio was measured by 
reversed phase CSP-HPLC (I-A column, 35% acetonitrile in water with 0.1% formic acid 
additive, 5 uL injection volume, 1.5 mL/min; monitored at 265 nm) at time points spanning 1 to 
90 minutes. Aliquots of 60 μL were withdrawn from the reaction vessel and quickly diluted in 40 
μL of stock 3:1 ACN:H2O solution at 0 °C before analysis (see Figure S3.4 for a representative 
example). Plots of ee versus time, and of ln(1/ee) versus time were generated from the data 
described in Tables S3.12-S3.14, and resulted in the respective graphs shown below (Figure 
S3.4).  










Table S3.12. Enantiomeric excess measured at various timepoints with HPLC spectra, trial 1. 
Trial 1 
Entry 1 2 3 4 5 6 
Time (s) 69.00 185.00 310.00 725.00 1507.00 3613.00 
ee (x 10-2, %) 0.494 0.356 0.188 0.118 0.112 0.092 





Table S3.13. Enantiomeric excess measured at various timepoints with HPLC spectra, trial 2. 
Trial 2 
Entry 1 2 3 4 5 6 7 
Time 123.00 247.00 361.00 479.00 602.00 1204.00 5393.00 
ee (x 10-2, %) 0.432 0.246 0.178 0.148 0.118 0.118 0.114 




Table S3.14. Enantiomeric excess measured at various timepoints with HPLC spectra, trial 3. 
Trial 3 
Entry 1 2 3 4 5 6 7 8 
Time 90.00 166.00 234.00 300.00 363.00 425.00 505.00 604.00 
ee (x 10-2, %) 0.458 0.336 0.226 0.176 0.154 0.120 0.116 0.110 









Figure S3.4. Plots measuring enantiomeric excess vs time. 
 
Racemization rate constants (krac) were derived from the slopes of the lines shown in 
Figure S3.4. The rate constants to enantiomerization, kenant, were obtained by halving krac values.  
Using a rearranged form (Eq. S3.1B) of the Eyring equation described above (Eq. S3.1), the free 
activation energies of racemization (ΔG‡rac) and enantiomerization (ΔG‡enant) were determined. 




















1 0.00402 29.372 0.00201 29.948 
30.03 
kcal/mol 
2 0.00300 29.615 0.00150 30.192 
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Chapter IV 
Atropselective Halogenation of Troponoids 
4.1. Introduction 
 Atropisomerism, a form of chirality arising from restricted rotation about a chiral axis, 
plays an important role in a number of scientific pursuits including ligand development (e.g. 4.1,1  
Figure 4.1),2 molecular devices,3 and drug discovery.4  While such rotationally restricted scaffolds 
are ubiquitous among modern therapeutics, single-atropisomer drugs are rarely created by design, 
and are instead frequently based on natural products (e.g. 4.25 and 4.3,6 Figure 4.1).7 Given the 
critical importance of chirality in drug development,8 and the potential target selectivity increases 
of single-atropisomer drugs, they are also becoming increasingly prevalent in de novo drug design 
(4.4,9 Figure 4.1).10 As was discussed in Chapter 3, this paradigm shift has the potential to usher 
in a new wave of atropisomerically pure drugs that have enhanced selectivity profiles over 
analogous racemic or racemizable compounds.  Synthetic efforts towards selective formation of 
single-atropisomer bioactive molecules therefore constitute an essential area of study that is 
rapidly garnering increasing attention from medicinal, synthetic, and physical chemists alike 




 Approaches involving applications of various chiral reagents are described in the literature. 
One classic example of this strategy is the work of Bringmann, who was able to perform an 
asymmetric CBS reduction of lactone 4.5 using a chiral reducing agent (S)-oxazaborolidine 4.6 to 
access 4.7 (a precursor to natural product dioncopeltine A) with excellent selectivity (Figure 
4.2A).11 Chiral auxiliaries have also found utility in this regard. In 2012, Colobert and coworkers 
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reported a highly atropselective synthesis of the biaryl moiety (4.10) of vancomycin using a 
ß-hydroxysulfoxide auxiliary (Scheme 4.1B).12 More widely studied, however, are techniques for 
atropselective cross-coupling, which by nature are more efficient transformations since no 
attachment/removal of an auxiliary is required. The first reported example of an atropselective 
cross-coupling was published by Makoto Kumada in 1975 (Scheme 4.1C).13 Using ligands 4.14 
and 4.15 he was able to access binapthyl compound 4.13 via a chiral phosphine-nickel catalyst. 
While this transformation was achieved with modest selectivity, it represents a breakthrough in 
atropselective synthesis and has set the stage for numerous advancements in this field. One such 
example comes from the laboratory of Buchwald and coworkers, who reported efficient syntheses 
of axially chiral biaryl amides (such as 4.18, Scheme 4.1D). These were reported in high yields 
and enantioselectivities via an asymmetric Suzuki coupling with KenPhos 4.19 as a ligand.14 
 Despite these advancements, atropselective synthetic methods are often stifled by the 
exceptionally high rotational barriers (>28 kcal/mol) needed to maintain configurational stability. 15 
This is especially problematic in the development of atropselective transformations for biological 
studies, where physiological conditions and metabolic processes can further influence these 
barriers.16 The following chapter describes a solution to these challenges by outlining a new 
synthetic strategy to access enantioenriched troponoids. Troponoids are bioactive non-benzenoid 
aromatic molecules that are predicted to have remarkably high barriers compared to the 5- and 6-
membered rings commonly found in drugs (see Chapter 3 for more details). This is due to their 
decreased external bond angles and increased sensitivity to the so-called “buttressing effect” 
(Figure 4.2A).17  However, other features such as tropylium characteristics,18 ring puckering,19 
and decreased aromaticity20 could influence the rotational barriers as well.  To the best of our 
knowledge, the only troponoid known to be atropisomeric is colchicine (4.3, Figure 4.1A, ΔG‡ = 
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22 kcal/mol) and related analogs. Interestingly, while it would be expected to racemize within 
minutes at room temperature, an added stereocenter renders the aS form more thermodynamically 
favorable.6 The only other troponoid known to possess any degree of atropisomerism is bistropone 
homodimer 4.20, which has a relatively low barrier to isomerization (ΔG‡ = 20.7 kcal/mol) such 
that it can only undergo chiral resolution at decreased temperatures (Figure 4.2B).21 Given the 
growing interest in troponoid drug development by our group22 and others,23 as well as the 
importance of atropisomerism throughout the field of chemistry, the development of an 
asymmetric, catalytic method of single-atropisomer troponoid synthesis would significantly 
advance biological studies on these molecules. To date, no such methods exist. 
 
To address this limitation, we turned our attention to atropselective halogenation. This 
technique has recently emerged as a viable synthetic strategy towards accessing enantioenriched 
benzamides,24 biaryls,25 quinazolinones,26 quinolines,27 and other scaffolds (Scheme 4.2A).28 
These transformations are typically dynamic, kinetic resolutions that are mediated by bifunctional 
organocatalysts capable of recognizing specific substrate conformations through hydrogen-
bonding interactions.29 However, these methods have found limited application in the synthesis of 
single-atropisomer drugs and drug candidates.30 We therefore began our studies by investigating 
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atropselective troponoid synthesis via a peptide-catalyzed halogenation strategy developed by 
Scott Miller’s group at Yale University.24-26 This approach exploits differences in rotational 
barriers around a chiral axis before and after bromination and has been applied to a range of 
scaffolds including benzamides (i.e. 4.25  4.26, Scheme 4.2B),24 which are close troponoid 
homologs. Prior studies indicate that effective catalysis is contingent on certain structural features 
of the peptide (e.g. 4.29l),26 primarily revolving around functional groups capable of forming 
H-bond contacts between the catalyst and the substrate.31 These include the basic 
β-dimethylaminoalanine (Dmaa) residue (which is capable of targeting acidic moieties on the 




More recent 1H-NMR and DFT studies further support this hypothesis.33 Furthermore, 
selectivity is likely provided by substrate H-bond donor and acceptor groups flanking the 
bromination site (see Chapter 3 for details). As these features are shared by our synthetic 
troponoid scaffolds, we became intrigued by the possibility of using these peptides to halogenate 
troponoids (i.e. 4.27  4.28), and thus initiated a collaboration with the Miller group to develop 
the first ever method for atropselective troponoid synthesis. 
 
4.2. Catalyst Identification 
 Our studies began with a screen of peptide-based catalysts for the bromination of 
amidotroponoid 4.27 using the conditions described in Scheme 4.3. Our choice of catalysts was 
guided by previous reports from the Miller group on analogous scaffolds,24,26 wherein the Dmaa 
residue was embedded into a sequence that was capable of adopting a β-turn geometry (i.e., 
H-bonding between the i and i+3 residues, Scheme 4.2, shown in red).32,34 These characteristics 
were predicted to facilitate selective complexation with one atropisomer of (±)-4.27 over the other. 
 
 In the absence of catalyst, bromination of 4.27 was nonselective and sluggish (Scheme 4.3). In 
the presence of triethylamine as a catalyst, however, the reaction provided 50% conversion of racemic 
4.28. Site-selectivity was confirmed by synthesis of the authentic isomer via the regioselective 
oxidopyrylium cycloaddition/ring-opening strategy discussed in Chapter 3. Upon observing identical 
1H-NMR profiles, we began to assess peptide-based catalysts for this transformation at a variety of 
temperatures. Where possible, the reactions were monitored by 
1H-NMR and run to full conversion. 




 Gratifyingly, peptides 4.29a, 4.29i, 4.29l, 4.29o, and 4.29q (highlighted in blue in Table 
4.1) were discovered to promote conversion to bromotroponoid 4.28 in roughly 40-50% ee. 
Consistent with previous reports, these catalysts are known to be capable of adopting β-turn 
geometries that have been demonstrated to be necessary for enantioselectivity in related 
scaffolds.33,35 Effective catalysts were found to share several other structural characteristics, 
including a Dmaa residue at the i position. A preliminary investigation into the impact of the i 
residue provided some insights into the mechanism of bromination (Figure 4.3). It was found that 
increasing the pKa of this functionality (as in the case of the tetramethyl guanidine (Tmga), Entry 
12) resulted in a nonselective reaction. Similarly, π-methyl histidine- and threonine-based catalysts 
4.29z and 4.29aa (Entries 27 and 28, respectively) also resulted in racemic reactions. New 
synthetic constructs with aryl rings at the i position (4.29t, 4.29u, 4.29v; Entries 21-23) were 
synthesized in hopes of engaging in favorable π/π stacking interactions between the catalyst and 
substrate. This proved not to be the case. The nature of substrate/catalyst complexation is 
contingent on many factors, and is the result of multiple dynamic processes and interactions. The 
change in both steric and electronic factors may both be responsible for these peptides adopting an 
unfavorable geometry.  
 
 The efficacy of peptide-catalyzed reactions is often particularly sensitive to functionality 
at the i+2 position.26 This position plays a key role in determining certain structural attributes of 
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the peptide.33 Upon examining this residue, we observed pronounced differences in selectivity 
resulting from seemingly minor alterations (as in 4.29a, 4.29b, 4.29c; see Figure 4.4). Indeed, in 
prior desymmetrization bromination studies, enantiodivergent catalysis has been observed using 
similar catalysts, featuring either a cyclopropyl or an aminoisobutyramide residue which differ by 
only 2 amu.36 While this effect is not fully understood, a linear correlation has previously been 
observed between enantioselectivity and the τ(i+2) angle in the bromination of axially chiral 
quinazolinones. This angle is a function of the dihedral ϕ and ψ angles of the i+2 position and 
impacts the nature of the β-turn geometry.33 Accordingly, a difference of 36% ee was observed 
(Entries 2 and 3). Additionally, a similar effect was observed when comparing cycloheptyl- and 
cyclooctyl-substituted catalysts 4.29n and 4.29o (Entries 15 and 16), wherein selectivity was 
doubled with addition of a single methylene unit in a substituent with existing steric bulk.  
 
 Having identified the Boc-Dmaa-DPro-Aib sequence to be optimal, we began to assess i+3 
substituents. In so doing, we again observed a high degree of sensitivity of catalytic activity 
towards seemingly subtle structural changes to the peptide scaffold. In addition to changes in 
peptidic secondary structural attributes, a more obvious steric element may also be in effect. While 
the degree of enhancement observed across the span of several i+2 residues (Acpc, Acbc, Aib) is 
likely too large to be explained by sterics alone, an interesting trend was observed between valine, 
isoleucine, and tert-leucine-substituted peptides. While valine at the i+3 position was found to 
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deliver bromotroponoid 4.28 in up to 50% ee, isoleucine substitution decreased catalytic activity 
by nearly half (32% ee, Entry 19), and tert-butyl leucine was nonselective (Entry 20; see Figure 
4.5). This trend is reflected in the reported A-values of isopropyl and tert-butyl substituents, 
potentially suggesting a steric component to achieving favorable substrate-catalyst interactions.37 
Moreover, a preliminary screen of various C-terminal functionality did not yield any improvement 
over peptide leads 4.29a, 4.29i, 4.29l, 4.29o, or 4.29q, highlighting the methyl ester endcap as a  
suitable protecting group and thus setting the stage for further reaction optimization. 
 
 
4.3. Optimization of the Reaction Conditions 
 Having identified catalysts 4.29a/4.29l and 4.29q as capable of delivering 4.28 in 40% and 
50% ee respectively, we looked more closely at probing reaction conditions. These results are 
summarized in Table 4.2. Of note, while it was discovered that catalyst 4.29q was capable of 
delivering comparable selectivity at 5 mol% as compared to 10 mol% (Entries 28 and 27, Table 
4.2), the majority of these studies were performed using 10% catalyst loading. Interestingly, it was 
found that stoichiometric peptide proved deleterious to the reaction (Entry 23), and that more dilute 
concentrations – while not substantially affecting selectivity – proved detrimental to the isolated 




 We next turned our attention to a screen of bromination reagents. Previous reports from 
the Miller lab demonstrate profound selectivity differences depending on the bromonium source.24-
26 We thus compared bromination reagents N-bromophthalimide (NBP), N-bromoacetamide 
(NBA), and N-bromosaccharin (NBSac) to NBS. Brominating reagent NBS was found to 
outperform the others in terms of conversion, yield, and selectivity (Entries 8, 10, 12 and 13). 
However, NBP demonstrated comparable selectivity. We hypothesize that this might be an effect 
of the dibrominated amide byproduct (Figure 4.6). Whereas succinimide and phthalimide have 
similar pKas (9.638a and 8.3,38b respectively), acetamide (pKa = 17)39 and saccharin (pKa = 1.6)40 
are well outside of this range, which may facilitate non-selective peptide/substrate contacts, or 
alter their protonation states altogether. Notably, chlorination reagents were also briefly assessed 
(Entries 14 and 15) and found to deliver substantially lowered selectivities and decomposition of 
substrate to an unidentifiable reaction mixture. However, further investigation of chlorination is 
warranted. 
 
 Temperature effects were also examined. While colder conditions proved beneficial, NBS 
dissolution was poor at temperatures below 0 °C. A similar issue was encountered while 
investigating solvent effects, where both NBS and substrate solubility were significantly impacted 
by decreases in temperature. Ultimately, CDCl3 proved to be the most effective solvent. 
Interestingly, impacts on conversion were observed when CHCl3 was used in place of CDCl3 (not 
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shown). Side reactions, potentially with chloroform additive amylene were observed, although the 
specific nature of these decomposition pathways is unclear at present. 
 Deuterated solvents served an additional purpose in allowing us to monitor the progress of 
these reactions by 1H-NMR. As such, the reactions were quenched when they reached full 
conversion, or when conversion appeared to plateau. Such quenches ranged from basic (Entries 
2-4) to acidic in nature. DMAP/Ac2O quenches were employed prior to procurement of reversed 
phase chiral HPLC supports, as a means of acetylating 4.28 for ease of normal phase purification. 
Head-to-head assessments (not shown) of this quench and an acid quench proved comparable in 
terms of selectivity. Acidic quenches were conducted by adding acidic solutions to a pre-made 1.0 
M pH 7 phosphate buffer, to reach an ultimate pH of 3. Curiously, the nature of this quench in 
certain instances lead to different outcomes in terms of selectivity (vide infra), prompting further 
mechanistic investigations. 
 
4.4. Mechanism-Driven Experiments 
Examination of certain elements of the reaction optimization inspired us to investigate 
mechanistic aspects of this reaction. This was largely borne out of the discovery of 
tentatively-assigned intermediate 4.34 upon monitoring the reactions by 1H-NMR. The 
intermediate appears to be related to the mechanism of bromination (see Scheme 4.4) and is 
characterized by long-range W-coupling between HC and the proximal methyl group. Further 
13C-NMR and HSQC studies, though not definitive, support this structural hypothesis (see 
Supporting Information). The intermediate was observed in all reactions that demonstrated 
selectivity, and was absent from the nonselective runs. It was also observed, fleetingly and at trace 
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levels, in a 1H-NMR study of background, uncatalyzed bromination (see Supporting Information 
for details).  
 
 
In cases where intermediate 4.34 was observed, its formation was rapid (immediate), while 
rearomatization to product was a slower process (in some cases taking up to a day to convert fully; 
see Scheme 4.4).  This is particularly perplexing given the increased electrophilicity of troponoids 
with respect to benzenoids. In all cases in which this intermediate was observed, consumption of 
NBS was observed almost instantly, while formation of brominated product was observed over 
significantly longer timeframes (3 hours – 6 days; see Tables 4.1 and 4.2), thus indicating that 
NBS is not the direct brominating reagent in this reaction. Overall, these initial observations 
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suggest that the sluggishness of the electrophilic troponoids have allowed us to observe phenomena 
that would be challenging to observe on a more reactive benzenoid.  
 
4.4.1. Characterization Attempts 
 Characterization of this intermediate is complicated by its low stability and resulting high 
reactivity. These traits coupled with the fact that it exists only fleetingly when in the absence of 
catalyst render definitive characterization a challenge. Attempts to isolate it via recrystallization 
were unsuccessful, and the molecule predictably proved unstable to a variety of chromatography 
conditions.  
 13C and HSQC NMR experiments, though not definitive, support the proposed structure of 
4.34. Of particular note, the 13C-NMR spectra of 4.34 in comparison to that of 4.28 shows three 
new signals characteristic of carbonyls (see Supporting Information). DEPT experiments are also 
under investigation to specifically study the nature of the putative sp3 carbon. Stoichiometrically, 
it makes sense that this sp3 carbon would be bonded to one proton and one bromine, and while 
proton He remains difficult to see by 
1H-NMR, there is potential evidence of its existence in the 
HSQC spectra (see Supporting Information for details). However, treatment of bromotroponoid 
4.28 to excess NBS and 20 mol% peptide 4.29a was found to lead to immediate formation of the 
intermediate by 1H-NMR. Identical conditions with succinimide in place of NBS lead to no 
reaction (Scheme 4.5). While it is possible that 4.34 and a gem-dibromo variant of 4.34 (as in 
4.34a) could coincidentally have identical 1H-NMR profiles, this remains unlikely. 
Stoichiometrically speaking, exclusive formation of gem-dibromo variant 4.34a directly from 4.27 
with only 1.1 equivalents of NBS (such as described in Scheme 4.3) would be impossible. 




4.4.2. Quench Studies 
 Upon further examination, it was found that in the presence of base, intermediate 4.34 is 
immediately quenched. However, quenching of the intermediate did not always lead to formation 
of bromotropolone product (Scheme 4.6). Upon allowing the reaction to run to full conversion of 
starting material – while in the presence of intermediate – it was observed that addition of base 
could lead to reversion back to starting material. This may potentially be explained by an 
interaction between intermediate 4.34 and product 4.28. However, both the choice of base and the 
reaction time preceding base addition appear to impact the degree to which the reversion occurs. 
For instance, in a head-to-head comparison, triethylamine was found to effect a higher degree of 
reversion than DMAP. As well, when peptide/substrate/NBS were allowed only 10 minutes to 
react prior to base addition, no base-catalyzed reversion to starting material was observed. While 
the origin of this effect remains unclear, it appears that the presence of bromotropolone 4.28 is 
necessary for reversion to starting material. It also remains a possibility that an early base quench 
may take place while some NBS is still present in the reaction. This residual NBS may serve to 




 An additional quench that was investigated was previously-reported methyl ketone-
containing troponoid 4.35b (Scheme 4.7). As the brominated variant of this molecule had been 
synthesized and characterized,41 any bromination of this compound could be reliably detected. 
Therefore, 4.27 was pushed to full conversion to 4.34 (with total consumption of NBS) before 
treatment with one equivalent of methyl ketone 4.35b (hypothesized to be capable of existing as 
4.35a in the presence of succinimide). While sluggish, bromination of 4.35b was observed to begin 
within 55 min, although no reversion of either tropolone to starting material was observed. 
Remarkably, this quench also appeared to lead to full racemization of bromotropolone 4.28, 
potentially through a racemization equilibrium as outlined in Scheme 4.7. While concrete 
conclusions cannot necessarily be drawn from these experiments, it is clear that intermediate 4.34 
is serving as a brominating reagent and is potentially responsible for the stunted selectivities 




4.4.3. Halogen Exchange 
 Given the inconsistency of the base quenches, we elected to reinvestigate acidic quenches 
instead. Remarkably, crude material showing no evidence of chlorotropolone 4.36 by 1H-NMR, 
upon treatment with an HCl-containing buffer, underwent conversion (to varying degrees) to 









Table 4.3. Halogenation exchange upon aqueous workup. 
 
Halogen exchange studies revealed that this conversion did not take place via direct 
substitution on the intermediate. While a linear relationship between intermediate and 
chlorotropolone may be inferred from Entry 1 (Table 4.3), closer examination reveals that this is 
not the case. Instead, it was observed that increasing amounts of intermediate lead to increasing 
chlorination in an exponential trend (Figure 4.7). For example, when a nearly 1:1 
product:intermediate (4.28 : 4.34) ratio is observed pre-quench, a 6:1 chloro:bromotropolone ratio 
is  observed post-quench (Entry 2). A similar effect is observed in Entry 3. Plotting of these ratios 
gave a second order polynomial fit (R2 = 0.9999), while a plot of the log gave a straight line with 
a very high degree of linearity (R2 = 0.9993). While the mechanistic underpinnings behind these 
observations at present remain unclear, further investigation may uncover the relationship between 
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intermediate 4.34 and the enantioselectivity of the peptide-catalyzed reaction. Interestingly, the 
enantioinduction of chlorotropolone 4.36 was found to be comparable to the most selective 
bromination reaction (52% ee, Table 4.3), though its presence creates purification challenges 
given the similar polarities of 4.28 and 4.36. Ultimately, it was discovered that changing the acid 
additive to H2SO4, as well as increasing the reaction time such that all intermediate had reacted, 
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4.5. Mechanistic Hypotheses 
 At the outset of these studies, we hypothesized that reaction of troponoid substrate with the 
catalyst would proceed via a transition state analogous to a previously reported atropselective 
halogenation (Figure 4.8).24,26 In such systems, 1H-NMR spectra of a 1:1 substrate/peptide 
complex shows evidence of such complexation in the form of chemical shift differences between 
the complex and both individual molecules. When such titration experiments were carried out on 
troponoid 4.27 with catalysts 4.29a, 4.29e, 4.29f and 4.29g, no significant chemical shifts were 
observed. While in and of itself not confirmation of the presence or absence of this binding mode,42 
it is perhaps indicative of a weaker binding interaction. This seems all the more likely when an 
equilibrium as described in Scheme 4.7 is invoked. Bromination at the substrate amide carbonyl 
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would block one of the necessary points of contact between substrate and catalyst in this binding 
model. Additionally, it remains a strong possibility that succinimide (pKa 9.6)38 deprotonates the 
troponoid (pKa ~6-7),43 rendering it incapable of coordinating with the peptide for this second 
binding interaction. In spite of this hypothesis, NBS emerged as the lead brominating reagent in 
the optimization. However, due to commercial availability, pKas of the amide byproducts were 
only studied within certain pKa ranges and thus interference with the proposed binding model 
(Figure 4.8C) remains possible. 
 
 Thus, the impacts of acid additives were preliminarily assessed. Choice of additive was 
guided by three necessary characteristics, namely: low reactivity towards bromination, low 
nucleophilicity, and a pKa44 high enough to avoid protonating the catalytic tertiary amine of the 
peptide. To this end, nitrophenols 4.40 and 4.41 (Tables 4.4A and 4.4B) were investigated.  
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Unfortunately, these were found to have the opposite effect of what was anticipated, and 
in fact in the case of 4.40 the selectivity of the reaction was almost completely destroyed (Entry 3 
vs Entry 4). Unforeseen complexation of these additives with catalyst, direct protonation of the 




 These aggregate mechanistic observations lead us to the hypotheses outlined in Figure 4.9 
In such a mechanistic model, nonlinear conversion of intermediate to chlorotropolone is explained, 
since intermediate formation is predicted to feed into formation of a chlorinated variant. The 
necessity of the presence of bromotropolone 4.28 alongside intermediate 4.34 for reversion to 
starting material in the presence of base may also be rationalized. Additionally, the stunted 
enantioselectivity of the reaction may be explained; if brominated product is indeed reacting with 
some version of this intermediate, lowered enantioinduction would be expected. Furthermore, if 




4.6. Impeding Formation of Intermediate 4.34 
 Driven by the hypothesis that intermediate 4.34 is somehow contributing to enantioerosion, 
we sought to impede its formation. We speculated we might be able to accomplish this and thus 
boost enantioselectivity by changing the mode of NBS delivery. Under previous conditions, NBS 
was added in one portion at the beginning of the reaction. Therefore, we investigated a slow 
addition mode of delivery, where 1.1 equivalents of NBS were added over a 2.5-hour time period. 
Unfortunately, this did not prove effective in increasing enantioselectivity (Entries 1 and 2, Table 
4.5). 
 
 We next sought to examine the effects of running the reaction under NBS-controlled low 
conversion, such that formation of an intermediate of the proposed structure 4.34 would be 
inhibited. Gratifyingly, a correlation with enantioselectivity was observed (Table 4.5). Under 
conditions where 1.1 equivalents of NBS provided 40% ee, it was discovered that 0.5 equivalents 
of NBS boosted the selectivity to 48%, a profound improvement. Further cutting the NBS down 
to 0.28 equivalents produced an additional enhancement to 52%, which remains one of our highest 
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ee’s thus far. These results shed light on the otherwise unclear nature of this reaction. While the 
resulting stifled conversions render reagent-controlled low conversion an impractical tactic for 
single-atropisomer troponoid synthesis, these results indicate that intermediate suppression is 
likely the path forward in optimizing this reaction. 
 
4.7. Conclusions 
 Herein, the first reported efforts at development of an atropselective synthesis of an axially 
chiral troponoid are described. Asymmetric peptide-based catalysis was investigated and found to 
be capable of delivering a bromotroponoid in high levels of enantioinduction at 75:25 er. During 
the course of these studies, mechanistic discoveries unveiled the existence of a non-aromatic 
intermediate that may be simultaneously indicative of atropselectivity while also stimulating 
enantioerosion. This bromine-containing intermediate was also found to facilitate delivery of a 
chlorotroponoid with substantially higher selectivity than was able to be provided by running the 
reaction with a chlorinating agent. While we have made several significant discoveries in the study 
of this novel reaction, there remains much to be uncovered, and work is currently ongoing to 
ascertain more information on the nature of this intermediate. The highly unstable nature of the 
intermediate renders definitive characterization difficult, and speaks to the challenges associated 
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4.9. Supplementary Experimental Details 
With the exception of those described in the sections below, all peptide catalysts were 
synthesized and provided by the Miller laboratory, and characterized by the Miller laboratory as 
previously published.S1 HPLC access and assistance was also provided by the Miller laboratory.  
 
4.9.1. General Information. 
All starting materials and reagents were purchased from commercially available sources 
and used without further purification, with the exception of CH2Cl2, which was purified on a 
solvent purification system prior to the reaction. All reactions were performed in oven- or flame-
dried glassware. Commercially available dibromodimethylhydantoin (DBDMH), N-
bromosuccinimide (NBS), and N-chlorosuccinimide (NCS) were purified by recrystallization from 
hot water.   
1H-NMR spectra were obtained on a Bruker 400 MHz spectrometer. 2D NMR spectra were 
recorded on Agilent 400, 500, or 600 MHz spectrometers. Chemical shifts are measured using the 
solvent residual peak as the internal standard (CHCl3 δ 7.26, MeOH δ 3.31, CH2Cl2 δ 5.32, DMSO 
δ 2.50), and reported as follows: chemical shift, multiplicity (s = singlet, bs = broad singlet, d = 
doublet, t = triplet, dd = doublet of doublet, q = quartet, m = multiplet, dd = doublet of doublets, 
ddd = doublet of doublet of doublets, dt = doublet of triplets, dq = doublet of quartet, ABq = AB 
quartet), coupling constant (Hz), and integration. 13C NMR shifts are measured using the solvent 
residual peak as the internal standard (CHCl3 δ 7.2, MeOH δ 49.0, DMSO δ 39.5), and reported as 
chemical shifts.  
Infrared (IR) spectral bands are characterized as broad (br), strong (s), medium (m), and 
weak (w). Microwave reactions were performed via the Biotage Initiator 2.5. Analytical thin-layer 
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chromatography (TLC) was performed using Silica Gel 60 Å F254 pre-coated plates (0.25 mm 
thickness). TLC Rf values are reported, with visualization accomplished by irradiation with a UV 
lamp or appropriate TLC stain. Purification via normal phase column chromatography was 
performed on the Biotage Isolera Prime, with Biotage SNAP 10g or 25g cartridges, in a solvent 
system of ethyl acetate and hexanes. Reversed phase chromatography was performed on the 
Biotage Isolera Prime with Biotage SNAP C18 12 g cartridges, in a solvent system of water and 
acetonitrile with a 0.05% trifluoroacetic acid additive. Column gradients are measured in terms of 
column volumes (CV). Mass spectra were recorded on a spectrometer by the electrospray 
ionization (ESI) technique with a time-of-flight (TOF) mass analyzer. HPLC analysis was 
conducted with an Agilent 1100 series instrument equipped with a diode array detector (λ = 265 
nm) and columns (chiral supports) from Daicel Chemical Industries (Chiralpak AS-H for normal 
phase, and Chiralpak IA and Chiralpak IC for reversed phase purification) at ambient temperature 
unless otherwise noted.  
 
4.9.2. Solution Phase Peptide Synthesis and Characterization 
 The majority of peptides used in these studies were synthesized and characterized as 
reported by the Miller laboratory.S1 Peptides 4.29t-v, however, were synthesized for this work. 
This was accomplished using the Boc protecting group strategy2 outlined in aforementioned prior 










Peptide S4.3 was synthesized as reported previously.S1 To a flask containing trimer S4.3 (84 mg, 
0.21 mmol), HOBt H2O (38 mg, 0.28 mmol, 1.3 eq) and a stir bar was added 
N-Boc-L-phenylalanine (Boc-Phe-OH; 68 mg, 0.25 mmol, 1.2 eq). The solid 
mixture was dissolved in dry CH2Cl2 (1.05 mL, 0.20 M with respect to S4.3). 
EDC HCl (54 mg, 0.28 mmol, 1.3 eq) was then added. The resulting solution 
was left to stir at RT as DIPEA (97 μL, 0.55 mmol, 2.6 eq with respect to S4.3) was slowly added. 
The solution was allowed to stir for 18 hours before being diluted with 20 mL CH2Cl2, poured into 
a separatory funnel, and washed with an equivalent volume of 10% aqueous (w/v) citric acid. The 
organic layer was separated and subsequently washed with an equivalent volume each of saturated 
aqueous NaHCO3 and brine. Organic layers were combined, dried over anhydrous sodium sulfate, 
filtered, and concentrated under reduced pressure to provide 4.29u as a white solid (105 mg, 74% 
yield). Rf = 0.76 in 10% MeOH in CH2Cl2. IR (thin film, KBr) 3323 (br), 2978 (w), 2360 (m), 
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2341 (m), 1745 (w), 1637 (w), 1454 (m), 1366 (m), 1270 (w), 1245 (m), 1170 (s), 701 (w), 669 
(w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.32 – 7.26 (m, 4H), 7.26 – 7.17 (m, 6H), 7.14 (d, J = 
7.6 Hz, 1H), 6.77 (s, 1H), 5.52 (d, J = 7.1 Hz, 1H), 4.82 (dd, J = 14.1, 7.5 Hz, 1H), 4.55 (q, J = 7.5 
Hz, 1H), 4.18 (dd, J = 8.0, 3.6 Hz, 1H), 3.66 (s, 3H), 3.61 – 3.53 (m, 1H), 3.13 (ddd, J = 21.2, 13.8, 
6.8 Hz, 3H), 3.01 – 2.99 (bs, 1H), 2.99 – 2.96 (bs, 1H), 2.80 (dt, J = 9.6, 7.5 Hz, 1H), 2.13 – 2.04 
(m, 1H), 1.93 – 1.82 (m, 1H), 1.71 – 1.63 (m, 1H), 1.61 – 1.50 (m, 1H), 1.45 (s, 3H), 1.40 (s, 9H), 
1.34 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 173.8, 172.4, 171.7, 170.5, 136.6, 136.4, 129.4, 
129.4, 128.5, 128.4, 127.1, 126.8, 79.9, 60.9, 57.2, 54.0, 53.3, 52.1, 47.2, 39.1, 38.0, 28.4, 27.9, 
25.9, 24.9, 24.6 HRMS (ESI+) m/z calculated for C33H45N4O7+: 609.3283. Found: 609.3221. 
 
Boc-[Phe-F5]-DPro-Aib-Phe-OMe (4.29t). 
Peptide S4.3 was synthesized as reported previously.S1 To a flask containing trimer S4.3 (84 mg, 
0.21 mmol), HOBt H2O (38 mg, 0.28 mmol, 1.3 eq) and a stir bar was added 
N-Boc-L-pentafluorophenylalanine (Boc-[Phe-F5]-OH; 89 mg, 0.25 mmol, 
1.2 eq). The solid mixture was dissolved in dry CH2Cl2 (1.05 mL, 0.20 M 
with respect to S4.3). EDC HCl (54 mg, 0.28 mmol, 1.3 eq) was then added. 
The resulting solution was left to stir at RT as DIPEA (97 μL, 0.55 mmol, 2.6 eq with respect to 
S4.3) was slowly added. The solution was allowed to stir for 12 hours before being diluted with 
20 mL CH2Cl2, poured into a separatory funnel, and washed with an equivalent volume of 10% 
aqueous (w/v) citric acid. The organic layer was separated and subsequently washed with an 
equivalent volume each of saturated aqueous NaHCO3 and brine. Organic layers were combined, 
dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Reversed 
phase chromatography of the crude residue with water/methanol was accomplished on a Biotage 
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Isolera Prime (SNAP 12g C18 silica gel column, solvent gradient: 10% methanol in water (3 CV); 
10-30% (4 CV), 30-100% (16 CV); methanol and water each contained 0.05% TFA; monitored at 
210 nm and 254 nm). Product fractions were combined and concentrated at 30 °C in vacuo, 
yielding 4.29t as a yellow foam/oil (75 mg, 50% yield). Rf = 0.72 in 10% MeOH in CH2Cl2.  IR 
(thin film, KBr) 3325 (br), 2980 (m), 1743 (w), 1711 (w), 1639 (s), 1521 (s), 1504 (s), 1441 (m), 
1366 (w), 1124 (m), 1002 (w), 974 (m), 701 (m), 607 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 
7.24 (d, J = 3.5 Hz, 2H), 7.21 – 7.15 (m, 3H), 6.67 (s, 1H), 6.16 (d, J = 9.2 Hz, 1H), 4.92 (dd, J = 
14.1, 8.2 Hz, 1H), 4.66 (td, J = 9.4, 4.2 Hz, 1H), 4.22 (dd, J = 7.2, 5.7 Hz, 1H), 3.71 (s, 3H), 3.67 
– 3.54 (m, 2H), 3.17 (dd, J = 13.8, 5.6 Hz, 1H), 3.09 – 2.89 (m, 4H), 2.21 – 2.03 (m, 3H), 1.98 – 
1.85 (m, 1H), 1.49 (s, 3H), 1.29 (s, 9H), 1.24 (s, 3H).. 13C NMR (100 MHz, CDCl3) δ 173.9, 
172.7, 170.8, 170.1, 155.3, 146.9 (m), 144.4 (m), 141.4 (m), 138.6 (m), 136.3, 136.1 (m), 129.3, 
128.4, 126.9, 110.9 (t), 79.9, 61.4, 57.3, 52.9, 52.3, 51.5, 47.5, 38.2, 28.4, 27.9, 27.2, 25.3, 25.2, 
23.6. HRMS (ESI+) m/z calculated for C33H40F5N4O7+: 699.2812. Found: 699.2852. 
 
Boc-3Pal-DPro-Aib-Phe-OMe (4.29v). 
Peptide S4.3 was synthesized as reported previously.S1 To a flask containing trimer S4.3 (50 mg, 
0.13 mmol), HOBt H2O (28 mg, 0.21 mmol, 1.3 eq) and a stir bar was 
added N-Boc-D-3-pyridylalanine (Boc-3Pal-OH; 41 mg, 0.15 mmol, 1.2 
eq). The solid mixture was dissolved in dry CH2Cl2 (1.05 mL, 0.20 M 
with respect to S4.3). EDC HCl (32 mg, 0.17 mmol, 1.3 eq) was then 
added. The resulting solution was left to stir at RT as DIPEA (26 μL, 0.15 mmol, 1.2 eq with 
respect to S4.3) was slowly added. The solution was allowed to stir for 20 hours before being 
diluted with 20 mL CH2Cl2, poured into a separatory funnel, and washed with an equivalent 
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volume of 10% aqueous (w/v) citric acid. The organic layer was separated and subsequently 
washed with an equivalent volume each of saturated aqueous NaHCO3 and brine. Organic layers 
were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced 
pressure. Chromatography of the crude residue with dichloromethane/methanol was accomplished 
on a Biotage Isolera Prime (SNAP 10g silica gel column, solvent gradient: 0% methanol in 
dichloromethane (3 CV); 0-1% (3 CV), 1-2% (5 CV); 2-5% (10 CV); 5-10% (10 CV); 10% (3 
CV); monitored at 210 and 254 nm). Product fractions were combined and concentrated at 30 °C 
under reduced pressure, yielding 4.29v as a clear foam/oil (29 mg, 38% yield). 1H NMR (400 
MHz, CDCl3) δ 8.51 – 8.44 (m, 1H), 8.44 – 8.40 (m, 1H), 7.55 – 7.49 (m, 1H), 7.23 – 7.17 (m, 
1H), 7.12 (d, J = 6.5 Hz, 3H), 7.07 (d, J = 6.8 Hz, 3H), 6.90 (d, J = 7.2 Hz, 1H), 5.24 (d, J = 8.9 
Hz, 1H), 4.80 (dd, J = 13.2, 6.1 Hz, 1H), 4.65 – 4.56 (m, 1H), 4.44 – 4.35 (m, 1H), 3.70 (s, 3H), 
3.65 – 3.58 (m, 1H), 3.54 – 3.43 (m, 1H), 3.13 (ddd, J = 33.9, 13.9, 6.0 Hz, 2H), 2.92 (dd, J = 14.0, 
5.0 Hz, 1H), 2.66 (dd, J = 14.0, 8.4 Hz, 1H), 2.29 – 2.18 (m, 1H), 1.96 – 1.83 (m, 3H), 1.51 (s, 
3H), 1.39 (s, J = 3.2 Hz, 3H), 1.34 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 173.8, 172.5, 171.9, 
170.4, 155.3, 150.9, 148.4, 137.2, 136.3, 132.3, 129.5, 129.3, 128.6, 128.5, 127.0, 123.5, 80.2, 
60.9, 60.5, 57.3, 53.1, 52.4, 47.7, 37.7, 35.7, 28.4, 27.3, 26.5, 25.3, 24.5, 21.2, 14.3. HRMS (ESI+) 








Note: Peptides 4.29i and 4.29j were synthesized by the Miller laboratory.  
Characterization of Boc-Dmaa-DPro-[α-Me, D-Phe]-Leu-OMe (4.29i): White, foamy solid, 
15% overall yield. Rf = 0.59 in 10% MeOH in CH2Cl2. 1H NMR (500 
MHz, CDCl3): δ 7.34 (d, J = 8.6 Hz, 1H), 7.30 – 7.20 (m, 3H), 7.14 (d, J 
= 7.0 Hz, 2H), 6.42 (s, 1H), 5.82 (d, J = 6.3 Hz, 1H), 4.75 – 4.62 (m, 1H), 
4.44 (q, J = 6.9 Hz, 1H), 4.26 (dd, J = 7.6, 4.0 Hz, 1H), 3.87 – 3.79 (m, 
1H), 3.72 (s, 3H), 3.66 – 3.58 (m, 1H), 3.56 (d, J = 13.7 Hz, 1H), 3.10 (d, J = 13.8 Hz, 1H), 2.63 
(dd, J = 12.1, 7.6 Hz, 1H), 2.41 (dd, J = 12.2, 6.9 Hz, 1H), 2.27 (s, 6H), 2.25 – 2.18 (m, 1H), 2.13 
– 2.01 (m, 2H), 2.01 – 1.87 (m, 2H), 1.77 – 1.60 (m, 4H), 1.41 (s, 9H), 1.38 (s, 3H), 0.98 – 0.85 
(m, 6H). IR (thin film, KBr) 3324 (br), 2955 (br), 1748 (m), 1652 (s), 1522 (s), 1456 (m), 1367 
(w), 1284 (w), 1163 (m), 860 (w), 708 (w) cm-1.   13C NMR (150 MHz, CDCl3): δ 174.0, 173.6, 
171.3, 170.4, 155.8, 137.1, 130.8, 127.9, 126.6, 79.9, 61.7, 60.2, 53.4, 51.9, 51.0, 50.8, 47.5, 45.6, 
40.8, 40.2, 28.8, 28.4, 24.6, 24.1, 23.1, 21.7. HRMS (ESI+) m/z calculated for C32H52N5O7+: 
618.3561. Found: 618.3452. 
 
Characterization of Boc-Dmaa-DPro-[α-Me, L-Phe]-Leu-OMe (4.29j): White, foamy solid, 
12% overall yield.  1H NMR (600 MHz, CDCl3): δ 7.26–7.24 (m, 2H), 
7.24–7.21 (m, 1H), 7.19 (d, J = 8.1 Hz, 1H), 7.16–7.12 (m, 2H), 6.32 (s, 
1H), 5.58 (s, 1H), 4.57 (ddd, J = 9.6, 7.8, 4.9 Hz, 1H), 4.33–4.30 (m, 1H), 
4.28 (dd, J = 9.7, 4.2 Hz, 1H), 3.84–8.79 (m, 1H), 3.72–3.69 (m, 1H), 3.69 
(s, 3H), 3.49 (q, J = 8.6 Hz, 1H), 3.09 (d, J = 13.8 Hz, 1H), 2.55–2.48 (m, 1H), 2.47–2.42 (m, 1H), 
2.24 (s, 6H), 2.21–2.15 (m, H), 2.15–2.06 (m, 1H), 1.94–1.87 (m, 1H), 1.87–1.79 (m, 1H), 1.79–
1.70 (m, 2H), 1.63–1.57 (m, 1H), 1.41 (s, 3H), 1.38 (s, 9H), 0.94 (dd, J = 10.7, 6.5 Hz, 6H). 13C 
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NMR (150 MHz, CDCl3): δ 173.9, 173.4, 171.2, 170.3, 155.7, 136.9, 130.8, 127.9, 126.5, 79.9, 
61.6, 60.2, 59.6, 51.8, 50.9, 50.7, 47.4, 45.5, 40.7, 40.1, 28.8, 28.4, 24.5, 24.1, 23.0, 21.6. IR (thin 
film, KBr) 3750 (br), 2955 (br), 2360 (w), 1748 (m), 1652 (s), 1540 (m), 1456 (m), 1367 (w), 
1284 (w), 1163 (m), 860 (w), 708 (w) cm-1. HRMS (ESI+) m/z calculated for C32H52N5O7+: 
618.3561. Found: 618.3867. 
 





General Procedure. To an oven-dried 1-dram vial equipped with peptide catalyst 4.29d (1.84 mg, 
0.003 mmol, 0.1 eq) was added troponoid 4.27 (8.3 mg, 0.300 mmol), a magnetic 
stir bar, and CDCl3 (1.5 mL, 0.02 M). The solution was allowed to stir at ambient 
temperature. N-Bromosuccinimide (NBS, 5.9 mg, 1.1 eq) was then added (all at 
once) to the stirring solution at room temperature after the sides of the vial were wrapped in 
aluminum foil. The reaction was further protected from light by turning off the lights in the 
ventilation hood. Reaction progress was monitored by 1H-NMR in an NMR tube wrapped in 
aluminum foil when not inside the NMR spectrometer. When the reaction reached full conversion 
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of starting material (26 hours), it was quenched by addition of a flake of DMAP and 3 drops of 
acetic anhydride and allowed to stir at ambient temperatures overnight. Acetylation progress was 
monitored by thin layer chromatography. The solvent was removed under reduced pressure, and 
the crude reaction mixture was purified by chromatography (Biotage Isolera Prime, 10 g silica gel 
column, elution solvents: dichloromethane with 2% acetic acid additive, and acetone. Solvent 
gradient: 0% acetone in dichloromethane (3 CV); 0-20% (10 CV); 20% (4 CV); 20-25% (8 CV); 
25-30% (2 CV); 30-60% (5 CV)). Product fractions were concentrated to yield 4.28a as a yellow 
oil (5.1 mg, 43% yield). Rf= 0.32 in 20% acetone in dichloromethane. IR (thin film, KBr) 3545 
(br), 2938 (m), 2855 (m), 1770 (s), 1633 (s), 1591 (w), 1446 (w), 1298 (m), 1269 (s), 1223 (m), 
1184 (w), 1135 (s), 1073 (m), 873 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.73 (bs, 1H), 3.95 (s, 
3H), 3.91 – 3.79 (m, 1H), 3.68 – 3.52 (m, 1H), 3.30 – 3.18 (m, 2H), 2.44 (s, 3H), 2.37 (s, 3H), 1.83 
– 1.47 (m, 6H). 13C NMR (100 MHz, CDCl3; partial) δ 166.9, 137.2, 57.1, 47.3, 42.3, 26.4, 26.0, 
25.2, 24.6, 20.8. HRMS (ESI+) m/z calculated for C17H21BrNO5+: 398.0598. Found: 398.0602. 
HPLC 70:30 er (Chiralpak AS-H, 1.5 mL/min, 8% ethanol in hexanes, regulated at 40 °C, 254 










General Procedure A. N-Bromosuccinimide (NBS, 1.1 equiv.) was added to a 0.02 M solution 
of tropamide 4.27 (17.3 mg, 0.062 mmol, 1 equiv) and catalyst 4.29q (3.5 mg, 
0.006 mmol, 0.1 equiv) in CDCl3 (3.12 mL) at 0 ºC (while shielded from light). 
The reaction was allowed to stir for 72 hours. The reaction was then diluted with 
4 mL of DCM, transferred to a separatory funnel, and quenched with an equivalent volume of a 
pH 3 phosphate buffer (made by diluting 1.7 mL of 2.0 M aqueous sulfuric acid with 12 mL of 1.0 
M pH 7 phosphate buffer), and extracted 3x. The combined organics were dried over sodium 
sulfate, filtered, and concentrated under reduced pressure. Reversed phase chromatography of the 
crude residue with water/acetonitrile was accomplished on a Biotage Isolera Prime (SNAP 12g 
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C18 silica gel column, solvent gradient: 10% acetonitrile in water (3 CV); 10-23% (8 CV), 23-
35% (8 CV), 35-100% (6 CV); acetonitrile and water each contained 0.05% TFA). Product 
fractions were combined, extracted with excess DCM (3x, Σ = 60 mL), filtered through Na2SO4 
and concentrated at 30 °C in vacuo, yielding 4.28 as a waxy brown/yellow solid (11.2 mg, 50% 
yield) with 1H-NMR data consistent with previously reported data. See Section 3.10.4 in Chapter 
3 for characterization data. HPLC 75:25 er (Chiralpak IA, 1.5 mL/min, 35% acetonitrile in water 




General Procedure B. The same procedure as outlined above was followed, but the reaction was 
run at ambient temperature. Such reactions were monitored for conversion by 1H-NMR. Upon 
reaching full conversion, they were quenched according the procedure described above. 
 
General Procedure C. The same procedure as outlined above (Procedure B), with N-
chlorosuccinimide (NCS) used in place of N-bromosuccinimide (NBS). Additionally, the reaction 
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was instead quenched with a pH 3 phosphate buffer that was made by diluting 1.0 M phosphate 
buffer with enough 2.0 M HCl solution to bring the total solution to a pH of 3. 
 
General Procedure D. The same procedure as outlined above was followed (A and B only), but 
the reaction was instead quenched with a pH 3 phosphate buffer that was made by diluting 1.0 M 




one (4.36).   
 
Procedure C. To a solution of 2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1-
carbonyl)cyclohepta-2,4,6-trien-1-one 4.27 (8.0 mg, 0.029 mmol) and 4.29a (1.6 
mg, 0.0029 mmol) in CDCl3 (1.44 mL, 0.02 M) was added N-chlorosuccinimide 
(NCS, 4.2 mg, 0.032 mmol) at ambient temperature at which point the reaction 
immediately turned red. The reaction was transferred to an oven-dried NMR tube for monitoring 
the progress of the reaction and was also shielded from light. The reaction proved sluggish, and 
NCS took 7 days to be fully consumed. After 9 days, 4.27 and 4.36 were present in a 1:0.78 ratio, 
and conversion appeared to have plateaued. The reaction was then diluted with 4 mL of DCM, 
transferred to a separatory funnel, and quenched with an equivalent volume of a pH 3 phosphate 
buffer (made by diluting 10 mL of 1.0 M pH 7 phosphate buffer with 2.0 M HCl until a pH of 3 
was reached), and extracted 3x. The combined organics were dried over sodium sulfate, filtered, 
and concentrated under reduced pressure to yield a yellow oil. Reversed phase chromatography of 
the crude residue with water/acetonitrile was accomplished on a Biotage Isolera Prime (SNAP 12g 
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C18 silica gel column, solvent gradient: 10% acetonitrile in water (3 CV); 10-23% (8 CV), 23-
35% (8 CV), 35-100% (6 CV); acetonitrile and water each contained 0.05% TFA). Product 
fractions were combined, extracted with excess DCM (3x, Σ = 50 mL), filtered through Na2SO4 
and concentrated at 30 °C under reduced pressure to yield a yellow oil (1.0 mg, yield not 
calculated). 1H NMR (400 MHz, CDCl3) δ 7.01 (s, 1H), 4.01 (s, 3H), 3.86 – 3.66 (m, 2H), 3.27 – 
3.13 (m, 2H), 2.46 (s, 3H), 1.79 – 1.62 (m, 6H). 13C NMR (100 MHz, CDCl3; partial) δ 157.2, 
121.5, 56.9, 47.2, 42.3, 26.1, 25.7, 25.3, 24.6. HR-LCMS (ESI+) m/z calculated for 
C15H19ClNO4+: 312.0997. Found: 312.0999. HPLC 53:47 er (Chiralpak IC, 1.0 mL/min, 65% 










Procedure D. To a solution of 2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1-
carbonyl)cyclohepta-2,4,6-trien-1-one 4.27 (11.2 mg, 0.040 mmol) and 4.29a 
(2.18 mg, 0.004 mmol) in CDCl3 (2.02 mL, 0.02 M) was added 
N-bromosuccinimide (NBS, 7.9 mg, 0.044 mmol) at 0 °C. The reaction was 
transferred to an oven-dried NMR tube for monitoring the progress of the reaction 
and shielded from light. After allowing the reaction to stir at 0 °C for 3 hours, the reaction was 
then diluted with 4 mL of DCM, transferred to a separatory funnel, and quenched with an 
equivalent volume of a pH 3 phosphate buffer (made by diluting 10 mL of 1.0 M pH 7 phosphate 
buffer with 2.0 M HCl until a pH of 3 was reached), and extracted 3x. The combined organics 
were dried over sodium sulfate, filtered, and concentrated under reduced pressure to yield a 
mixture of 4.28 and 4.36 in a 1:6 ratio by 1H-NMR. Reversed phase chromatography of the crude 
residue with water/acetonitrile was accomplished on a Biotage Isolera Prime (SNAP 12g C18 silica 
220 
gel column, solvent gradient: 10% acetonitrile in water (3 CV); 10-23% (8 CV), 23-35% (8 CV), 
35-100% (6 CV); acetonitrile and water each contained 0.05% TFA). Product fractions were 
combined, extracted with excess DCM (3x, Σ = 60 mL), filtered through Na2SO4 and concentrated 
at 30 °C under reduced pressure to yield a yellow oil (2.2 mg, 17% yield) with 1H-NMR data 
consistent with previously reported data. HPLC 76:24 er (Chiralpak IC, 1.0 mL/min, 65% 




4.9.4. NMR Studies on Racemic and Uncatalyzed Conversion 
Uncatalyzed Conversion. To a solution of 2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1-
carbonyl)cyclohepta-2,4,6-trien-1-one 4.27 (5.5 mg, 0.020 mmol) in CDCl3 (1.0 mL, 0.02 M) 
was added N-bromosuccinimide (NBS, 3.9 mg, 0.022 mmol). The reaction was transferred to an 
oven-dried NMR tube for monitoring the progress of the reaction and shielded from light. For 
1H-NMR spectra showing conversion, see Section 4.9.6. 
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Racemic Conversion with 0.1 Equivalents of Base. 
To an oven-dried 1-dram vial was added a solution of 2-hydroxy-7-methoxy-5-methyl-4-
(piperidine-1-carbonyl)cyclohepta-2,4,6-trien-1-one 4.27 (8.3 mg, 0.030 mmol) in CDCl3 (1.5 mL, 
0.02 M) and N-bromosuccinimide (NBS, 5.9 mg, 0.033 mmol). The reaction was allowed to stir 
at ambient temperature before adding triethylamine (0.4 μL, 0.003 mmol; added as a stock solution 
in CDCl3). The reaction was transferred to an oven-dried NMR tube for monitoring the progress 
of the reaction and shielded from light. 1H NMR (400 MHz, CDCl3) δ 7.15 (s, 1H), 7.03 (s, 1H), 
6.99 (s, 1H), 4.00 (s, 3H), 3.96 (s, 3H), 3.89 – 3.54 (m, 4H), 3.25 – 3.17 (m, 4H), 2.43 (s, 3H), 
2.41 (s, 3H), 1.80 – 1.41 (m, 12H). (1H-NMR of crude reaction. Triethylamine and succinimide 
peak values omitted for clarity. For 1H-NMR spectrum, see Section 4.9.6.) 
 




one (4.28). In the presence of stoichiometric base, NBS was discovered to result in decomposition 
of the reaction. Accordingly, brominating agent dibromodimethylhydantoin was used instead. To 
a solution of 2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1-carbonyl)cyclohepta-2,4,6-trien-1-
one 4.27 (10.8 mg, 0.039 mmol) in CDCl3 (1.30 mL) was added dibromodimethylhydantoiin 
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(DBDMH, 14.25 mg, 0.05 mmol), followed by triethylamine (5.4 μL, 0.039 mmol). The reaction 
was allowed to stir for 2 hours at rt before quenching with pH 3 phosphate buffer and extracting 
with CH2Cl2. Combined organics were dried over Na2SO4, filtered, and concentrated under 
reduced pressure to yield 4.28 as a pale yellow/brown waxy solid (5.6 mg, 88% yield) with 1H-
NMR data consistent with previously reported data. HPLC 51:49 er (Chiralpak IA, 1.5 mL/min, 
35% acetonitrile in water with 0.1% formic acid). See Section 3.10.4 in Chapter 3 for 










4.9.5. NMR Studies on Intermediate 4.34 
 
 
Synthesis and Tentative Characterization. To an oven-dried, 1-dram vial was added peptide 
catalyst 4.29a (2.0 mg, 0.004 mmol, 20 mol%), troponoid 4.27 (5.2 mg, 0.019 mmol) in CDCl3 
(0.937 mL, 0.02 M) and a magnetic stir bar. The solution was allowed to stir at ambient 
temperature. N-Bromosuccinimide (NBS, 7.3 mg, 0.041 mmol, 2.2 eq) was then added (all at once) 
to the stirring solution at room temperature after the sides of the vial were wrapped in aluminum 
foil. The reaction was immediately transferred to an oven-dried NMR tube and wrapped in 
aluminum foil. 1H NMR (400 MHz, CDCl3) δ 6.41 (q, J = 1.4 Hz, 1H), 3.63 (s, 3H), 3.62 (s, 1H), 
2.12 (d, J = 1.3 Hz, 3H). 13C NMR (150 MHz, CDCl3) δ 180.1, 178.8, 177.4, 164.7, 135.2, 131.8, 
57.6, 57.1, 46.6, 42.6, 28.4, 25.9, 25.3, 24.5. Not stable on LCMS, or long-lived enough to study 
by HMBC or NOE correlation experiments. For 13C and HSQC data, see Section 4.9.6.  
 
Base Quench Study.  
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To an oven-dried, 1-dram vial was added peptide catalyst 4.29c (1.7 mg, 0.003 mmol), 
troponoid 4.27 (8.7 mg, 0.031 mmol) in CDCl3 (1.56 mL, 0.02 M) and a magnetic stir bar. The 
solution was allowed to stir at ambient temperature. N-Bromosuccinimide (NBS, 6.1 mg, 0.034 
mmol) was then added (all at once) to the stirring solution at room temperature after the sides of 
the vial were wrapped in aluminum foil. Reaction was monitored by 1H-NMR for 90 minutes to 
ensure full conversion of starting material. At this time, all NBS was fully converted, and the 
ratio of product 4.28 to intermediate 4.34 was 1:3.7. 
Reaction 1 (top, blue): 4-Dimethylaminopyrydine (DMAP, 3.8 mg, 0.031 mmol) was 
added. After 10 minutes, 1H-NMR showed total disappearance of intermediate 4.34. The ratio of 
starting material 4.27 to product 4.28 was 2:3. 
Reaction 2 (bottom, red): Triethylamine (4.4 μL, 0.031 mmol) was added. After 10 
minutes, 1H-NMR showed total disappearance of intermediate 4.34. The ratio of starting material 
4.27 to product 4.28 was 3:2. 
 
Halogenation Exchange Study. Refer to Section 4.9.3, General Procedure C. These results are 
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